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Parkinson’s disease (PD) is characterized by progressive motor impairment attributed
to progressive loss of dopaminergic (DAergic) neurons in the substantia nigra pars
compacta. Additional clinical manifestations include non-motor symptoms such as
insomnia, depression, psychosis, and cognitive impairment. PD patients with mild
cognitive impairment have an increased risk of developing dementia. The affected brain
regions also show perturbed metal ion levels, primarily iron. These observations have led
to speculation that metal ion dyshomeostasis plays a key role in the neuronal death of this
disease. However, the mechanisms underlying this metal-associated neurodegeneration
have yet to be completely elucidated. Mammalian models have traditionally been used
to investigate PD pathogenesis. However, alternate animal models are also being
adopted, bringing to bear their respective experimental advantage. The nematode,
Caenorhabditis elegans, is one such system that has well-developed genetics, is amenable
to transgenesis and has relatively low associated experimental costs. C. elegans has a well
characterized neuronal network that includes a simple DAergic system. In this review we
will discuss mechanisms thought to underlie PD and the use of C. elegans to investigate
these processes.
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INTRODUCTION
Parkinson’s disease (PD) is the second most prevalent age-related
neurodegenerative disorder of the central nervous system, after
Alzheimer’s disease (AD). Idiopathic or sporadic PD affects
approximately 1% of people over 65 years old (Hirtz et al.,
2007). PD is characterized by severe motor impairment, which
is attributed to profound depletion of striatal dopamine (DA)
due to progressive loss of dopaminergic (DAergic) neurons in
the substantia nigra pars compacta, a region in the basal ganglia
that is crucial in voluntary motor functions (Hornykiewicz and
Kish, 1987; Wooten, 1997; Braak et al., 2003). PD is also char-
acterized by proteinaceous neuronal inclusions known as Lewy
bodies (Irizarry et al., 1998). Current PD therapies focus mainly
on correcting this DA depletion. Although effective in alleviating
symptoms, these treatments lose their efficacy over time and do
not halt the underlying neurodegeneration (Smith et al., 2012).
Determining the mechanisms contributing to PD neurodegener-
ation is critical to facilitate the design of effective therapies to halt
further neuronal loss.
While some PD cases are monogenic, arising from single
point mutation in a specific gene, more than 90% of the cases
are idiopathic (Table 1). The mechanisms underlying idiopathic
PD are not fully understood. However, increasing evidence sug-
gests that oxidative stress may be a major contributing factor to
neuronal loss. This is evidenced by increased levels of oxidized
lipids, proteins and nucleic acids in PD brains (Dexter et al.,
1989a, 1994; Jenner and Olanow, 1996; Yoritaka et al., 1996;
Alam et al., 1997a,b). Oxidative stress is thought to arise from
a variety of mechanisms including mitochondrial dysfunction,
neuroinflammation, perturbed DAmetabolism and environmen-
tal toxins (Thomas and Beal, 2007; Hwang, 2013). Metal ion
dyshomeostasis has also been hypothesized to cause oxidative
stress, following evidence that PD brains exhibit increased total
iron concentration (Dexter et al., 1991; Gotz et al., 2004; Oakley
et al., 2007). In addition, levels of zinc are increased and copper
decreased in the substantia nigra (Dexter et al., 1991).
Investigating the molecular basis of neurodegeneration in vivo
relies on animal models, with mammalian models typically being
used. All animal models have inherent experimental limitations
and none fully replicate all aspects of a disease such as PD. As
greater understanding of PD is gained and new hypotheses pro-
posed there is a parallel need for animal models to be updated and
modified to further our understanding. Establishing new trans-
genic models can have a significant lead-time with some animal
systems being less suited to genetic modification. These particular
limitations can be alleviated by use of a less complex animal, such
as Caenorhabditis elegans.
C. ELEGANS AS A NEURODEGENERATION MODEL
C. elegans is a free-living nematode, approximately 1mm in
length, which exists as either a self-fertilizing hermaphrodite or
as a male (Figure 1). C. elegans can be cultured inexpensively
on an E. coli lawn on agar media and has a short defined life
cycle (Brenner, 1974). The rapid life cycle coupled with a high
reproductive capacity makes C. elegans a suitable tool for muta-
genesis and compound screening approaches. C. elegans also has
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Table 1 | PD associated and susceptibility genes and corresponding C. elegans homologs.
PARK designationa PD-associated genes
Gene Type of mutation Status C. elegans homolog
PARK1 SNCA Dominant Confirmed No known homolog
PARK2 Parkin Recessive Confirmed pdr-1
PARK3 Unknown Dominant Not validated since first publication Unknown
PARK5 UCHL-1 Dominant or risk
factor
Unconfirmed; conflicting reports (Healy et al.,
2006)
ubh-1
PARK6 PINK1 Recessive Confirmed pink-1
PARK7 DJ-1 Recessive Confirmed djr-1.1 and drj-1.2
PARK8 LRRK2 Dominant Confirmed lrk-1
PARK9 ATP13A2 Recessive Confirmed catp-6
PARK11 GIGYF2 Dominant Unconfirmed; conflicting reports (Pankratz et al.,
2002; Bras et al., 2009; Tan et al., 2009)
No known homolog
PARK12 Unknown Risk factor Confirmed Unknown
PARK13 HTRA2 Dominant or risk
factor
Unconfirmed; conflicting reports (Strauss et al.,
2005; Simon-Sanchez and Singleton, 2008)
No known homolog
PARK14 PLA2G6 Recessive Confirmed Potential homologs: C45B2.6,
D1037.5, F47A4.5, H23L24.2,
T04B2.5, and W07A8.2
PARK15 FBXO7 Recessive Confirmed No known homolog
PARK16 Unknown Risk factor Confirmed Unknown
PARK17 VPS35 Dominant Confirmed vps-35
PARK18 EIF4G1 Dominant Not validated since first publication
(Chartier-Harlin et al., 2011)
ifg-1
PARK19 DNAJC6 Recessive Recently published (Edvardson et al., 2012;
Koroglu et al., 2013)
dnj-25
PARK20 SYNJ1 Recessive Recently published (Krebs et al., 2013; Quadri
et al., 2013)
unc-26
PD susceptibility genesb
Gene Protein C. elegans homolog
MAPT Tau ptl-1
GBA Beta-glucosidase gba-1, gba-2, gba-3, and gba-4
MC1R Melanocyte-stimulating hormone receptor No known homolog
ADH1C Alcohol dehydrogenase 1C H24K24.3 and Y50D4C.2
HLA locus Major histocompatibility complex No known homolog
aPARK designation represents genes that are putatively linked to PD in chronological order of their identification.
bCertain polymorphisms or mutations in these genes pose a risk factor for PD.
an adult lifespan of approximately 3 weeks and is an established
model of biological aging. Additionally, the C. elegans genome has
been fully sequenced which has revealed that about 80% of C. ele-
gans genes have human homologs and at least 42% of human
disease-related genes have a C. elegans homolog (Consortium,
1998; Culetto and Sattelle, 2000; Lai et al., 2000). Functional
studies of corresponding or related human genes can be done
via mutation (where available) or RNA interference (RNAi) (Fire
et al., 1998; Hamamichi et al., 2008; Ruan et al., 2010).
To complement these approaches or in the absence of endoge-
nous homologs, C. elegans can be transgenically manipulated
to express human disease associated genes in specific cell types,
including neurons (Faber et al., 1999; Lakso et al., 2003; Brandt
et al., 2009; McColl et al., 2009, 2012). Adult hermaphrodite
C. elegans have 302 neurons, a neuronal network that is stereo-
typical between animals and which possesses most of the major
neurotransmitter systems found in mammals, including DAergic
neurons (White et al., 1986; Rand and Nonet, 1997; Bargmann,
1998). C. elegans are also optically transparent, which in con-
junction with fluorescent protein reporters, allows for in vivo
visualization of neurons, such as in Figure 2 (Chalfie et al., 1994;
Nass et al., 2002; Chew et al., 2013).
As with other animal models, use of C. elegans to model dis-
ease is always tempered by an awareness of the limitations of
cellular and anatomical differences. For example, C. elegans lack
a vascular system and the somatic tissues of adult C. elegans are
post-mitotic. Despite these obvious differences, key discoveries
in C. elegans have been readily translated to vertebrate research.
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FIGURE 1 | An adult C. elegans hermaphrodite. The diagram shows
the key anatomical features and the DAergic neurons (green) of
C. elegans. The DAergic neurons include four cephalic (CEP) neurons,
two anterior deirid (ADE) neurons, and two posterior deirid (PDE)
neurons. Males have six additional DAergic neurons located in the tail
(not shown).
FIGURE 2 | The anterior DAergic neurons of an adult C. elegans
hermaphrodite. The neurons are visualized by the translational expression
of GFP driven by the promoter of the DA transporter (Pdat−1::GFP). The key
features highlighted include the cell bodies and dendritic processes of the
four CEP neurons (arrows) and the cell bodies of the two ADE (chevrons).
C. elegans was used to identify genes that are involved in regu-
lating programmed cell death (Hedgecock et al., 1983; Ellis and
Horvitz, 1986). dsRNA gene expression regulation was character-
ized in C. elegans and led to development of RNAi, a tool widely
used in functional genomics (Fire et al., 1998). Additionally, the
conserved effects of the insulin/insulin growth factor-1 signal-
ing pathway on longevity were first noted in C. elegans mutants
(Friedman and Johnson, 1988; Kenyon et al., 1993; Dorman et al.,
1995; Murakami and Johnson, 1996; Kimura et al., 1997). C. ele-
gans research has also linked iron metabolism to restless leg
syndrome (Catoire et al., 2011). The findings in C. elegans were
predictive of the role of ferritin in human tissue.
PARKINSON’S DISEASE
The hallmark PD symptoms are motor deficits, which include
resting tremor, rigidity, slowness in movement (bradykinesia)
and posture instability. In the majority of PD cases, these clin-
ical manifestations only appear when approximately 50–70% of
nigral neurons are lost and approximately 80% of striatal DA is
depleted (Hornykiewicz and Kish, 1987; Kish et al., 1988; Orth
and Schapira, 2002). This DA deficiency leads to the observed
motor impairments because DA is an essential motor control
neurotransmitter. In addition to DAergic degeneration, exten-
sive neurodegeneration and atrophy occurs in other nerve cell
types and brain regions as PD advances. The regions affected
include the hippocampus, thalamus, and neocortex. This addi-
tional neurodegeneration leads to non-motor symptoms that
include insomnia, depression, psychosis and cognitive impair-
ment (Braak et al., 2003; Weintraub et al., 2011; Smith et al.,
2012). These non-motor symptoms worsen over time, for exam-
ple, an estimated 80% of PD patients with mild cognitive impair-
ment develop dementia (Janvin et al., 2006; Buter et al., 2008;
Hely et al., 2008). The etiology of the neurodegeneration leading
to cognitive impairment remains unclear.
PD is also characterized by neuronal inclusions, Lewy bodies
and Lewy neurites, which mainly contain aggregated α-synuclein
(Forno, 1996; Spillantini et al., 1997; Irizarry et al., 1998). Alpha-
synuclein is a 140-amino acid peptide encoded by the SNCA gene
and is predominantly located at presynaptic terminals. It is highly
expressed in the substantia nigra, hippocampus, neocortex, thala-
mus and cerebellum (Ueda et al., 1993; Nakajo et al., 1994; Iwai
et al., 1995; Recchia et al., 2004). These brain regions are highly
impacted by neurodegeneration in PD pathology. Several herita-
ble point mutations, A30P, A53T, E46K, H50Q, and G51D, and a
triplication of the SNCA gene are implicated in autosomal domi-
nant forms of familial PD (Polymeropoulos et al., 1997; Kruger
et al., 1998; Singleton et al., 2003; Zarranz et al., 2004; Appel-
Cresswell et al., 2013; Proukakis et al., 2013). These findings have
initiated numerous studies into the involvement of α-synuclein in
idiopathic PD pathology.
Although several possibilities have been proposed, the func-
tion of α-synuclein remains unknown. Alpha-synuclein KO mice
have impaired spatial learning and working memory suggesting
some involvement in cognitive function (Kokhan et al., 2012).
Sequestration of the protein in Lewy bodies may contribute
to cognitive impairment seen in advanced PD. Alpha-synuclein
over-expression in transgenic mice inhibits DA synaptic release
while α-synuclein deficiency causes decreased vesicle-bound stri-
atal DA (Abeliovich et al., 2000; Nemani et al., 2010). This
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suggests that α-synuclein is involved in synaptic transmission
by regulating DA release. Alpha-synuclein deficiency may lead
to unregulated DA release, which when coupled with loss of
DAergic neurons, leads to the striatal DA depletion observed
in PD. Under normal physiological conditions, α-synuclein neg-
atively modulates the dopamine transporter (DAT), which is
required for re-uptake of synaptically released DA (Wersinger and
Sidhu, 2003). This implies that α-synuclein deficiency caused by
sequestration in Lewy bodies may lead to increased DA re-uptake,
causing increased concentration of intracellular DA. High levels
of unbound intracellular DA have been shown to be neurotoxic
(Olanow and Arendash, 1994; Luo et al., 1998; Offen et al., 1999;
Lee et al., 2001).
Other studies suggest that α-synuclein may be a microtubule-
associated protein (MAP) as it interacts with tubulin (Alim
et al., 2002, 2004), with α-synuclein deficiency postulated to
lead to microtubule dysfunction. Microtubules provide structural
scaffolding in neurons and so their dysfunction would compro-
mise neuronal integrity leading to neuron death. Alpha-synuclein
sequestration in Lewy bodies appears to have significant impli-
cations in PD pathology, potentially by inhibiting the normal
functions of α-synuclein, which may include facilitating cog-
nitive function, synaptic transmission and stabilizing neuronal
morphology. However, the underlying mechanisms that trigger
DAergic neuronal death and α-synuclein aggregation in idio-
pathic PD require further investigation.
C. ELEGANS AND DAergic NEURONS
C. elegans hermaphrodites have a comparatively simple DAergic
system comprising eight neurons in total: six anterior DAergic
neurons, which include four cephalic (CEP) neurons and two
anterior deirid (ADE) neurons, and two posterior deirid (PDE)
neurons (Figures 1, 2). Males have six additional DAergic neu-
rons located in the tail (Sulston et al., 1975). DA synthesis,
storage and transport mechanisms are conserved in C. elegans
and DAergic nerve endings and synaptic vesicles have DA levels
similar to those in mammalian neurons (Fuxe and Jonsson, 1973;
Bargmann, 1998).
The functions of DAergic neurons have been investigated using
laser ablation, a technique which can target a specific neuron
while leaving neighboring neurons intact. The loss of DAergic
neurons revealed that they are important for food searching
and the basal slowing response upon sensing food (Sawin et al.,
2000; Hills et al., 2004). Exposure to exogenous DA resulted in
decreased egg laying, slowed defecation and paralysis (Schafer
and Kenyon, 1995; Weinshenker et al., 1995; Hills et al., 2004;
McDonald et al., 2006). Studies of mutations in cat-2, the tyrosine
hydroxylase which is the rate limiting enzyme in DA synthesis,
showed loss of basal slowing response and decreased touch habit-
uation suggesting that DA signaling is necessary for mechanosen-
sation (Sawin et al., 2000; Sanyal et al., 2004). These findings
suggest that DAergic neurons are important for locomotion, asso-
ciative learning, food searching, food sensing, egg-laying and
defecation.
Most models of DAergic neurodegeneration in C. elegans
are induced through exposure to neurotoxins and some metals,
which selectively ablate DAergic neurons. These toxins include
6-hydroxydopamine (6-OHDA), l-methyl-4-phenylpyridinium
(MPP+), methylmercury (MeHg), and manganese (Table 2)
(Nass et al., 2002; Braungart et al., 2004; Settivari et al., 2009;
VanDuyn et al., 2010). When exposed to 6-OHDA, C. elegans
show a progressive and selective DAergic neuron degeneration
and loss as evidenced by formation of blebs in axonal and den-
dritic membranes. (Nass et al., 2002; VanDuyn et al., 2010).
C. ELEGANS AND α-SYNUCLEIN
Although C. elegans lacks a human α-synuclein homolog,
α-synuclein expression has been investigated in transgenic C. ele-
gans. The targeting of transgene expression in C. elegans body
wall muscle cells has been used to explore the toxicity of several
disease-associated proteins. Body wall muscles run longitudinally
along the length of the nematode and are essential for loco-
motion. Functional disruption of these cells causes a clear and
robust paralysis phenotype (McColl et al., 2009, 2012). In PD
research, green or yellow fluorescent protein-tagged α-synuclein
was expressed in the body-wall muscle of C. elegans to visu-
alize α-synuclein aggregation in vivo (Hamamichi et al., 2008;
van Ham et al., 2008). These lines have been used to screen
RNAi libraries, revealing 20 neuroprotective genes whose knock
down enhanced α-synuclein aggregation. One of these genes
was the ortholog of human VSP41, a key lysosomal trafficking
protein that protects against toxicity of DA-derived neurotoxins
(Hamamichi et al., 2008; Ruan et al., 2010). Another genome-
wide RNAi screen revealed 80 genes that when knocked down
accelerated formation of α-synuclein inclusions. These genes,
which appear to suppress inclusion formation, are predominantly
involved in vesicular transport and lipid metabolism (van Ham
et al., 2008). These findings suggest that defects in the endosomal-
lysosomal and ER-Golgi vesicular trafficking system pathways
may be implicated in α-synuclein toxicity.
Additionally, neurodegenerative processes can also be studied
directly in C. elegans neurons. Over-expression of wild type and
A53Tmutant α-synuclein under the control of pan-neuronal pro-
moter, aex-3 and under the DAergic neuron specific promoter,
dat-1, caused loss of DAergic neurons (Lakso et al., 2003; Cao
et al., 2005). Two neuroprotective endoplasmic reticulum (ER)
associated proteins, TorsinA and Rab1 A, were found to amelio-
rate α-synuclein toxicity and prevent neuron loss (Cao et al., 2005;
Cooper et al., 2006), suggesting that α-synuclein toxicity affects
the ER-Golgi vesicular trafficking system. Another model over-
expressing wild type or mutant α-synuclein under the control of
the pan-neuronal promoter, unc-51, was used to screen an RNAi
library for genetic modifiers that either suppress or exacerbate α-
synuclein toxicity. Knock down of four genes that are involved
in synaptic endocytosis enhanced α-synuclein toxicity (Kuwahara
et al., 2008), suggesting that impaired endocytosis may contribute
to α-synuclein dysfunction seen in PD pathology.
Wild type and A53T mutant (human) α-synuclein have been
transgenically over-expressed via the C. elegans DAergic neuron
specific promoter, dat-1 (Lakso et al., 2003; Cao et al., 2005).
A screen of 115,000 compounds in cells and then C. elegans
identified four 1,2,3,4-tetrahydroquinolinones antagonists of α-
synuclein toxicity (Su et al., 2010). Another larger screen revealed
that several 8-hydroxyquinolines could ameliorate α-synuclein
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Table 2 | C. elegans Parkinson’s disease models.
Gene Construct/allele namea Expression pattern Phenotype References
α-synuclein (human wild
type)
Pdat-1::α-synuclein DAergic neurons DAergic neurodegeneration,
motor deficits, reduced DA
and α-synuclein accumulation
in DAergic neurons
Lakso et al., 2003;
Kuwahara et al., 2006;
Cao et al., 2005
Paex-3::α-synuclein Pan-neuronal DAergic neurodegeneration Lakso et al., 2003
Punc-51::α-synuclein Endocytosis, motor and
developmental defects
Kuwahara et al., 2008
Psnb-1::α-synuclein Mitochondrial stress Ved et al., 2005
Punc-54::α-synuclein::GFP Body wall muscles α-synuclein accumulation Hamamichi et al., 2008
Punc-54::α-synuclein::YFP α-synuclein accumulation van Ham et al., 2008
Pacr-2::α-synuclein Motor neurons Reduced motor movements Lakso et al., 2003
Pmec-7::α-synuclein Touch-receptor neurons Impaired touch sensitivity Kuwahara et al., 2008
α-synuclein (human
mutant)
Pdat-1::α-synuclein (A30P),
(A53T), (A56P), and (A76P)
DAergic neurons DAergic neurodegeneration Karpinar et al., 2009
Pdat-1::α-synuclein (A53T) DAergic neurodegeneration Lakso et al., 2003
Pdat-1::α-synuclein (A30P) and
(A53T)
Reduced DA and α-synuclein
accumulation in DAergic
neurons
Kuwahara et al., 2006
Punc-51::α-synuclein (A53T)
and (A30P)
Pan-neuronal Endocytosis, motor and
developmental defects
Kuwahara et al., 2008
Punc-119::α-synuclein (A53T) Mitochondrial stress Ved et al., 2005
Paex-3::α-synuclein (A53T) DAergic neurodegeneration,
motor deficits
Lakso et al., 2003
Pacr-2::α-synuclein (A53T) Motor neurons Reduced motor movements Lakso et al., 2003
Pmec-7::α-synuclein (A53T) Touch-receptor neurons Impaired touch sensitivity Kuwahara et al., 2008
GFP Pdat-1::GFP DAergic neurons Visualizes the DAergic
neurons
Nass et al., 2002
MAPT (human tau) Paex-3::tau (WT) Pan-neuronal Uncoordinated movement Kraemer et al., 2003
Paex-3::tau (V337M) Insoluble tau accumulation
Paex-3::tau (P301L) Nerve cord degeneration
LRRK2 Psnb-1::LRRK2 (WT) Pan-neuronal Mitochondrial stress Saha et al., 2009
Psnb-1::LRRK2 (R1441C) Mitochondrial stress
Psnb-1::LRRK2 (G2019S) Mitochondrial stress, DAergic
neurodegeneration and
reduced DA levels
Protein with tau like
repeats (ptl-1)
ok621 Null mutant Early on-set
neurodegeneration, egg
hatching defects and reduced
touch sensitivity
Gordon et al., 2008;
Chew et al., 2013
tm543 Partial deletion mutant Early on-set
neurodegeneration
Chew et al., 2013
Chemical treatment Phenotype References
6-hydroxydopamine
(6-OHDA)
DAergic neurodegeneration Nass et al., 2002; Cao
et al., 2005
MPTP/MPP+ DAergic neurodegeneration Braungart et al., 2004;
Pu and Le, 2008
Methyl mercury (MeHg) DAergic neurodegeneration VanDuyn et al., 2010
Manganese DAergic neurodegeneration and oxidative stress Settivari et al., 2009
Aluminum DAergic neurodegeneration VanDuyn et al., 2013
aConstruct name includes the promoter used to drive the transgene (promoter::transgene).
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aggregation and toxicity in C. elegans (Tardiff et al., 2012). The
underlying mechanism of protection is proposed to be via inter-
play betweenmetal homeostasis and proteotoxicity of aggregation
prone proteins. Interestingly another 8-hydroxyquinoline, PBT2,
has been found to reduce (the Alzheimer’s associated peptide)
Aβ toxicity in transgenic C. elegans (McColl et al., 2012). This
compound is currently under clinical trial as an AD therapeutic
(Lannfelt et al., 2008; Crouch et al., 2011).
OXIDATIVE STRESS AND METAL HOMEOSTASIS
Oxidative stress occurs from an imbalance between toxic oxidant
production and antioxidant activity, which leads to cellular dam-
age followed by apoptosis (Sies, 1991; Jenner, 2003). The main
reactive oxidants are the reactive oxygen species (ROS) and the
reactive nitrogen species (RNS). RNS have been comprehensively
reviewed elsewhere (Jomova et al., 2010). ROS, such as superox-
ide (O•−2 ) and hydroxyl radical (•OH) are normal by-products of
oxygen consumption during cellular metabolism, predominantly
in the mitochondria (Kepp, 2012). ROS levels are tightly regu-
lated by endogenous antioxidant enzymes, such as glutathione,
superoxidase dismutase (SOD), and catalase (Bains and Shaw,
1997; Sohal and Orr, 2012). It is important to stress that ROS
have essential functions in normal cell biology and are not always
inherently detrimental. For example, ROS are a component of
the innate immune system, particularly in phagocytes, which pro-
duce ROS to prevent colonization by microbes (Fang, 2004). ROS
are also utilized in cellular signaling (Hekimi et al., 2011) to
modulate the activity of kinases, phosphatases and transcription
factors. However, ROS are detrimental when their production
goes unchecked leading to damage of cellular lipids, proteins and
nucleic acids, and ultimately cell death (Pattison et al., 2002; Niki,
2009).
A way to counter the detrimental effects of ROS overproduc-
tion could be to administer antioxidant supplements or drugs,
such as, Vitamins A, C, and E and compounds that inhibit
ROS production. However, antioxidant therapeutic interventions
have not been successful in alleviating oxidative stress associ-
ated with neurodegenerative diseases. This is primarily due to the
inability of these compounds to effectively cross the blood brain
barrier (Halliwell, 2001). Additionally, these antioxidants when
administered in high doses have negative side effects by affect-
ing normal cellular processes that rely on ROS activity (Halliwell,
2001; Freeman and Keller, 2012). An understanding of the cause
of oxidative stress is vital to design better therapies to prevent
neurodegeneration.
Biological transition metals, such as iron, copper, zinc, mag-
nesium, nickel, cobalt, and manganese, are essential co-factors
for at least one-third to one-half of all proteins (Andreini et al.,
2008;Waldron et al., 2009). Iron and copper aremetabolically uti-
lized due to their ability to redox cycle, with iron being the most
abundant. However, in the event of metal ion misregulation, this
redox ability has the potential to produce toxic radicals via Haber-
Weiss and Fenton reactions leading to oxidative stress (Nunez
et al., 2012). Levels of these metal ions are reported to be per-
turbed in brains affected by various neurodegenerative diseases.
This has led to the metal ion dyshomeostasis hypothesis, which
proposes that the metal ion imbalance triggers increased ROS
production causing oxidative stress that eventually leads to neu-
ronal death. It is plausible that the observed metal imbalance is
just a symptom and not a cause of neurodegeneration. However,
several heritable neurodegenerative diseases are directly caused
by metal-ion misregulation. These progressive conditions include
aceruloplasminaemia and neuroferritinopathy, which result from
iron misregulation, and Menkes Disease and Wilson’s Disease,
which result from copper misregulation (Vulpe et al., 1993;
Yoshida et al., 1995; Harris et al., 1998; Curtis et al., 2001). These
diseases suggest that dyshomeostasis of brain metals is sufficient
to initiate neurodegeneration.
Iron is an essential metal in organisms because of its redox
ability (Cairo et al., 2002). For example, reactive iron is part of
the cytochrome complex in the mitochondrial respiration chain,
which is important for cellular energy production. It is a crucial
co-factor for catalase, an antioxidant that regulates hydrogen per-
oxide levels and also for heme proteins, which are essential for
vascular transport of oxygen and carbon-dioxide. In the substan-
tia nigra, iron is essential for DA synthesis (Youdim et al., 1984).
However, this reactivity also allows iron to catalyze production of
toxic hydroxyl radicals via Fenton chemistry:
Fe3+ + H2O2 → Fe2+ + HOO• + H+
Fe2+ + H2O2 → Fe3+ + OH− + •OH
Therefore, the concentration of unbound intracellular iron must
be kept low; a process regulated by iron storage and transport
proteins, such as ferritin (iron storage), ferroportin (iron efflux),
divalent metal transporter-1 (DMT-1, an iron transporter), and
transferrin (iron shuttling/uptake) (Lee and Andersen, 2010;
Gkouvatsos et al., 2012). Disruption in these homeostatic func-
tions could result in iron accumulation leading to oxidative
damage and loss of function of proteins that depend on iron as
a co-factor. This could potentially disrupt cellular respiration,
antioxidant activity, oxygen/carbon dioxide transport and DA
synthesis.
Copper is an important co-factor in the activity of redox active
proteins, such as ceruloplasmin (iron homeostasis), cytochrome
c oxidase (mitochondrial cellular respiration), Cu/Zn-superoxide
dismutase (antioxidant activity) and dopamine-b-hydroxylase
and tyrosinase, which are key proteins in DA synthesis
(Arredondo and Nunez, 2005; Kepp, 2012). Therefore, copper
imbalance in neurons may affect the function of these proteins.
Additionally, unbound copper concentration requires tight con-
trol due to its redox potential. Copper levels higher than 10−18 M
can initiate oxidative damage by facilitating ROS production (Rae
et al., 1999):
Cu+ + H2O2 → Cu2+ + OH− + •OH
Copper levels are predominantly regulated by ion importers,
copper efflux pumps (ATP7A and ATP7B), metallochaperones,
metalloregulators and other copper regulating proteins, such as,
ceruloplasmin (Cp), (Camakaris et al., 1999; Waldron et al., 2009;
Pang et al., 2013). Defects in these systems may result in increased
levels of unbound copper causing oxidative damage. In addi-
tion, copper misregulation may cause loss of function of the
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copper dependent proteins, with resultant negative implications
on iron homeostasis, cellular energy metabolism, oxidative stress
responses and DA synthesis.
PARKINSON’S DISEASE AND OXIDATIVE STRESS
PD brains show increased levels of oxidized macromolecules,
which can be used as an indirect measure of ROS levels.
Malondialdehyde, lipid hydroperoxides and 4-hydroxynonenal,
which are lipid peroxidation products, are increased in PD brains
(Dexter et al., 1989a, 1994; Yoritaka et al., 1996). PD brains also
show increased levels of 8-hydroxydeoxyguanosine (8-OHdG)
and protein carbonyls, which are products of DNA and protein
oxidation, respectively, (Alam et al., 1997a,b). Another marker
of elevated ROS levels in PD brains is increased SOD activity
in the substantia nigra (Marttila et al., 1988; Saggu et al., 1989).
SOD catalyzes the dismutation of superoxide (O•−2 ) into oxygen
and hydrogen peroxide, therefore its activity may increase as a
neuroprotective measure to cope with increased ROS levels.
Increased ROS levels not only lead to cellular damage but also
to production of oxidation by-products that are also potentially
neurotoxic. For example, 4-hydroxynonenal irreversibly modifies
α-synuclein aggregation in vitro, potentially leading to formation
of protofibrils, which are neurotoxic to cultured DAergic neu-
rons (Qin et al., 2007). Lipid hydroperoxides have been shown
to lead to oxidation of DA to 6-OHDA, a known neurotoxin
(Sauer and Oertel, 1994; Przedborski et al., 1995; Pezzella et al.,
1997; Lotharius and O’Malley, 2000). Additionally, α-synuclein
aggregation can be induced in vitro in the presence of hydrogen
peroxide (Hashimoto et al., 1999). This suggests that increased
ROS levels not only directly cause neuronal damage but also indi-
rectly contribute to DA depletion and α-synuclein aggregation,
which can further exacerbate PD progression.
Taken together, these findings suggest that PD brains are under
oxidative stress, which leads to neurodegeneration. However, the
mechanisms underlying the increase in ROS levels are not clearly
understood. Mitochondrial dysfunction, neuroinflammation, DA
autoxidation and environmental toxins have been implicated in
the increase of ROS in PD brains (Thomas and Beal, 2007; Jomova
et al., 2010; Hwang, 2013). Metal ion dyshomeostasis may also
lead to increased ROS production in PD. Generally, the sub-
stantia nigra has the highest distribution of iron in the central
nervous system. However, PD brains have more elevated lev-
els of iron in this region (Dexter et al., 1989b; Riederer et al.,
1989; Sofic et al., 1991; Good et al., 1992; Gerlach et al., 1994;
Vymazal et al., 1999; Haacke et al., 2007). The infusion of iron into
rat brains results in parkinsonism and behavioral changes (Ben-
Shachar and Youdim, 1991; Sengstock et al., 1993). Additionally,
in mice the 8-hydroxyquinoline metal ion chelator, clioquinol,
and over-expression of ferritin, an iron storage protein, both
prevent neurodegeneration in PD models (Kaur et al., 2003).
These findings suggest that iron may play a significant role in PD
neurodegeneration.
The elevated iron levels in the substantia nigra are proposed
to directly and indirectly contribute to increased ROS produc-
tion. Increased unbound iron levels can produce ROS, such
as superoxide, via Fenton chemistry (Halliwell and Gutteridge,
1986). Additionally, ferric ions can precipitate oxidation of DA
to 6-OHDA in the presence of hydrogen peroxide (Pezzella
et al., 1997). Superoxide and 6-OHDA have the ability to release
iron stored in ferritin and [4Fe-4S] cluster-containing enzymes
(Liochev and Fridovich, 1994). This can potentially lead to a
vicious cycle in which unbound iron increases levels of superox-
ide and 6-OHDA causing release of more unbound iron. This may
contribute to the progressive neurodegeneration observed in PD.
Iron dyshomeostasis not only contributes to ROS produc-
tion but also negatively impacts the function of proteins that use
iron as a co-factor. For example, tyrosine hydroxylase, the rate-
limiting enzyme in DA synthesis, depends on iron (Nagatsu, 1995;
Ponting, 2001). Therefore, an increase in iron as seen in PD brains
may increase DA synthesis, causing excess DA to be released into
the cytoplasm, whichmay lead to increased ROS production. This
iron-induced DA dysfunction not only inhibits the normal func-
tion of DA but may also lead to increased DA oxidation into the
neurotoxin 6-OHDA (Pezzella et al., 1997; Jiang et al., 2013).
In addition to increased ROS production and iron dyshome-
ostasis, PD brains also exhibit a reduction in metal ion storage
capacity and antioxidant activity. Ferritin is a key iron storage
protein and disruption of its function perturbs iron homeostasis.
PD brains have decreased ferritin levels (Dexter et al., 1991). This
potentially leads to iron storage deficiency, which allows unbound
reactive iron to accumulate in the substantia nigra, facilitating
ROS production (White and Munro, 1988; Dexter et al., 1991;
Connor et al., 1995). Neuroferritinopathy is a condition caused
by a genetic mutation of the ferritin light chain which disrupts
ferritin assembly, leading to iron accumulation and neurodegen-
eration in the basal ganglia, resulting in severe motor disorders
(Curtis et al., 2001; Vidal et al., 2003). In addition to decreased fer-
ritin levels, PD patients have decreased concentration and activity
of Cp (Kristinsson et al., 2012). Cp is a multi-copper oxidase that
oxidizes ferrous ions (Fe2+) to less reactive ferric ions (Fe3+).
This oxidation is essential for cellular iron uptake and efflux
by ferroportin and transferrin. Aceruloplasminaemia, a heritable
condition resulting from Cp deficiency, leads to iron accumula-
tion in the basal ganglia, neurodegeneration and motor problems
including dystonia and tremors (Harris et al., 1998).
PD brains have approximately 40% lower reduced glutathione
(GSH), an antioxidant enzyme that catalyzes the reduction
of ROS (Sofic et al., 1992). GSH also forms complexes with
other enzymes, such as glutathione peroxidase and glutathione
S-tranferases, to facilitate ROS reduction (Smeyne and Smeyne,
2013). Decreased antioxidant capacity likely contributes to the
oxidative stress seen in PD brains. These findings suggest that
defective metal ion transport and storage, decreased antioxidant
activity and increased reactive metal ion accumulation contribute
to oxidative stress leading to neurodegeneration.
C. ELEGANS : OXIDATIVE STRESS AND METAL ION HYPOTHESIS
Another link between PD and oxidative stress is gleaned from
studies of mutations in DJ-1 and PINK1, which are associated
with early onset PD (Bonifati et al., 2003; Valente et al., 2004).
DJ-1 and PINK1 have been shown to protect against oxidative
stress (Junn et al., 2005; Pridgeon et al., 2007). This was confirmed
inC. elegans by studying the nematode homologs, djr1.1 and pink-
1. The djr-1.1 knock-down and pink-1 mutant strains showed
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increased sensitivity to toxin-induced oxidative stress (Ved et al.,
2005; Samann et al., 2009). These C. elegans models comple-
ment the familial PD studies and strengthen the hypothesis that
oxidative stress contributes to PD pathology.
TransgenicC. elegans expressing α-synuclein in neurons exhib-
ited mitochondrial fragmentation attributed to α-synuclein inter-
action with mitochondrial membranes, affecting membrane
fusion (Kamp et al., 2010). Alpha-synuclein is localized in mito-
chondria, suggesting that α-synuclein dysfunction potentially
contributes to mitochondrial dysfunction in PD (Li et al., 2007).
In turn, mitochondrial dysfunction leads to ROS overproduc-
tion in the substantia nigra of PD brains, which leads to cellular
damage and cell death.
A recent study using electron paramagnetic resonance demon-
strated that unbound reactive iron levels increased during oxida-
tive stress in C. elegans (Rangel et al., 2012). Increased iron levels
in C. elegans resulted in increased protein oxidation, suggesting
that iron triggers increased ROS production. Iron chelation using
deferoxamine and over-expression of ferritin (ftn-1) reduced pro-
tein oxidation (Valentini et al., 2012). Knock down or deletion
of C. elegans SMF-1/2/3 (orthologs of human iron transporter,
DMT-1) partially inhibits DAergic neuronal death (Settivari et al.,
2009; VanDuyn et al., 2013). PD brains have increased iron levels,
decreased ferritin levels and increased DMT-1 levels, consistent
with defective iron transport and storage systems in PD brains
(Dexter et al., 1991; Salazar et al., 2008).
Knock down of SKN-1 (a C. elegans ortholog of Nrf2), a
transcription factor that regulates expression of glutathione S-
transferase, increased susceptibility to metal-induced neurode-
generation in DAergic neurons (VanDuyn et al., 2010; Settivari
et al., 2013). This finding and the observation that PD brains show
decreased levels of glutathione suggests that decreased antioxi-
dant activity contributes to PD pathology (Sofic et al., 1992).
Metal dyshomeostasis and oxidative stress may represent
an important component underlying idiopathic PD. C. elegans
possesses homologs of some of the iron homeostasis proteins
(Table 3) therefore the nematode can be used to further our
understanding of metal homeostasis in relation to PD. Even more
broadly, any findings can potentially be extended to familial auto-
somal PD because C. elegans also has homologs for the majority
of genes implicated in familial PD (Table 1). These features may
be exploited to investigate these genes and their interactions with
metal homeostasis.
Table 3 | C. elegans iron metal homeostasis proteins.
Human protein C. elegans homolog
Ferritin Ferritin 1 (FTN-1)
Ferritin 2 (FTN-2)
Ceruloplasmin F21D5.3
Ferroportin Ferroportin 1.1 (FPN-1.1)
Ferroportin 1.2 (FPN-1.2)
Ferroportin 1.3 (FPN-1.3)
Divalent metal-ion transporter SMF-1
SMF-2
SMF-3
THE MISSING LINK
Varied evidence supports the potential role of metal dyshome-
ostasis in PD neurodegeneration. However, the underlying mech-
anism that leads to metal imbalance still remains to be elucidated.
The interplay between tau, α-synuclein and microtubules, may
hold an answer to this question (Figure 3).
TAU, α-SYNUCLEIN, AND PARKINSON’S DISEASE
Tau is a MAP predominantly expressed in axons and is thought
to regulate the assembly of microtubules (Weingarten et al., 1975;
Kosik and Finch, 1987). Neurofibrillary tangles (NFTs) comprised
of hyperphosphorylated tau aggregates are a pathological hall-
mark of AD (Kidd, 1963; Wischik et al., 1988). Although not
often emphasized, tau has also been implicated in PD pathology.
Some PD patients have NFTs and in older people with parkin-
sonian symptoms, the severity of gait impairment appears to
correlate with the degree of NFT accumulation (Joachim et al.,
1987; Bancher et al., 1993; Schneider et al., 2006). Certain single-
nucleotide polymorphisms in the tau gene pose an increased
risk factor for PD (Zabetian et al., 2007; Edwards et al., 2010).
Tau KO mice have recently been reported to exhibit neuronal
iron accumulation, substantia nigra neuronal loss, parkinsonism
and cognitive deficits (Lei et al., 2012). Anti-psychotic DA D2
receptor antagonists, such as azaperone, suppress insoluble tau
aggregation in C. elegans (McCormick et al., 2013), suggesting an
interplay between tau and DA.
Increasing evidence highlights the importance of tau and
α-synuclein in PD pathology and indicates that the two pro-
teins significantly interact. Tau is co-localized with α-synuclein
in Lewy bodies (Arima et al., 1999). Tau and α-synuclein can
seed and promote each other’s polymerization to form insoluble
aggregates (Giasson et al., 2003; Geddes, 2005). Alpha-synuclein
has been shown to directly facilitate tau phosphorylation and
also to mediate glycogen synthase kinase 3 (GSK-3β, a ser-
ine/threonine protein kinase) catalyzed tau phosphorylation,
which is increased in PD brains (Jensen et al., 1999; Muntane
et al., 2008; Duka et al., 2009). This indicates that α-synuclein
may contribute to the increased GSK-3β activity, which leads to
tau hyperphosphorylation.
TAU, α-SYNUCLEIN, AND MICROTUBULE DYSFUNCTION
Based on the interaction between tau and α-synuclein, the dys-
function of the two proteins may disrupt two key functions
of microtubules: axonal transport and maintaining neuronal
morphology. Microtubule dysfunction precedes impaired axonal
transport (Cartelli et al., 2013). This was deduced from altered
mitochondria distribution and neurodegeneration in DAergic
neurons of mice exposed to MPTP. MPTP is known to destabilize
microtubules and impair axonal transport specifically in DAergic
neurons (Cappelletti et al., 2005; Ren et al., 2005; Morfini et al.,
2007). Administration of a microtubule stabilizer, Epothilone D,
attenuated further nigrostriatal neurodegeneration (Cartelli et al.,
2013), highlighting a potential link between axonal transport
disruption, microtubule dysfunction and neurodegeneration.
As a MAP, tau not only stabilizes microtubules but also regu-
lates transport by serving as a physical barrier and by interacting
with transport motor proteins, dynein and kinesin, to regulate
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FIGURE 3 | The oxidative stress and metal ion dyshomeostasis
cascade. This schematic summarizes the hypothesized mechanisms
that may lead to oxidative stress and metal dyshomeostasis in
DAergic neurons of C. elegans PD models. The unanswered questions
are also highlighted. Does tau hyperphosphorylation and α-synuclein
aggregation cause microtubule dysfunction? Are key metal ion
homeostasis proteins dependent on microtubules? Does metal ion
dyshomeostasis contribute to tau hyperphosphorylation and
α-synuclein aggregation? GST (glutathione S-transferase); SKN-1
(Nrf2 ortholog).
microtubule attachment and detachment (Jancsik et al., 1996;
Trinczek et al., 1999; Stamer et al., 2002; Mandelkow et al., 2003;
Magnani et al., 2007; Dixit et al., 2008). Tau over-expression
disrupts the transport of mitochondria and vesicles leading to
accumulation of mitochondria in distal parts of the neuron
(Ebneth et al., 1998; Stamer et al., 2002; Mandelkow et al.,
2003). Hyperphosphorylated tau filaments have been shown
to phosphorylate the kinesin light chain thereby triggering the
dissociation of kinesin from its cargo (Lapointe et al., 2009).
Phosphorylation of tau at the amino terminus can also impact
its inhibitory effect on axonal transport (Kanaan et al., 2012).
Mutant tau has been shown to cause “traffic jams” which inhibit
axonal transport (Shemesh et al., 2008). The tau dysfunction
observed in PD may negatively impact axonal transport, con-
tributing to neurodegeneration.
Alpha-synuclein is co-localized with tubulin in Lewy bodies
and co-purifies with microtubules. Additionally, when incu-
bated with tubulin, α-synuclein polymerizes tubulin into micro-
tubules (Alim et al., 2002, 2004). Immunofluorescence staining of
α-synuclein transfected COS-1 cells with α-synuclein and tubulin
antibodies, showed that α-synuclein co-localized predominantly
with microtubules (Alim et al., 2004). Alpha-synuclein binds
synaptic vesicles via its amino terminus and is involved in vesicle
trafficking (Jensen et al., 1999; Cooper et al., 2006). These find-
ings suggest that α-synuclein, like tau, is a MAP and is involved
in axonal transport of vesicles. Alpha-synuclein dysfunction likely
leads to impaired axonal transport.
Protein with tau-like repeats (PTL-1) is the only known
tau/MAP2 ortholog in C. elegans (Goedert et al., 1996). PTL-1
is important for maintaining C. elegans neuronal morphology
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(Chew et al., 2013). Null mutants for ptl-1 show accelerated
neurite branching and microtubule bundle disorganization in
mechanosensory and GABAergic neurons (Chew et al., 2013).
Microtubule changes in these neurons suggest a link between
tau deficiency and compromised neuronal integrity. In addition,
transfection of ptl-1 into non-neuronal cells promotes micro-
tubule assembly and bundling (Goedert et al., 1996).
Loss of function of tau and α-synuclein may result in signifi-
cant microtubule disruption that leads to neurodegeneration seen
in PD. Although the downstream effect of microtubule dysfunc-
tion in neurons remains to be elucidated, we can speculate that
cellular functions which rely uponmicrotubules will be disrupted.
The function of metal ion regulating proteins, such as ferroportin
and copper transporter (ATP7A), are dependent on axonal trans-
port (Cobbold et al., 2004; Moos and Rosengren Nielsen, 2006).
Microtubule disruption would likely lead to disrupted traffick-
ing of these metal ion homeostasis proteins. This in turn disrupts
metal ion homeostasis leading to accumulation of unbound reac-
tive metal ions and metal ion deficiency, resulting in oxidative
stress followed by neuronal loss.
CONCLUSION
Despite evidence pointing to the involvement of metal ion imbal-
ance and microtubule dysfunction in neurodegeneration, few
studies have attempted to link these two elements. We propose
that disrupted axonal transport and neuronal integrity greatly
impacts metal ion balance by hindering the trafficking of metal
ion homeostasis proteins and neuronal anti-oxidants (Figure 3).
Disrupting metal ion homeostasis is likely to result in oxidative
stress leading to neuronal loss. In addition, microtubule disrup-
tion may result in loss of synaptic connections due to altered neu-
ronal morphology causing synaptic transmission impairment.
The interplay between tau, α-synuclein andmetal dyshomeostasis
offers a new avenue of investigation. C. elegans has homologs for
many of the genes involved in iron regulation (Table 3) and can
be genetically manipulated to express transgenes in the absence of
homologs (Table 2); this may represent an ideal system in which
to investigate these questions.
ACKNOWLEDGMENTS
The Australian Research Council (ARC), the National Health
and Medical Research Council (NHMRC) of Australia, and
the Victorian Government’s Operational Infrastructure Support
Program supported this work.
REFERENCES
Abeliovich, A., Schmitz, Y., Farinas, I., Choi-Lundberg, D., Ho, W. H., Castillo,
P. E., et al. (2000). Mice lacking alpha-synuclein display functional deficits in
the nigrostriatal dopamine system. Neuron 25, 239–252. doi: 10.1016/S0896-
6273(00)80886-7
Alam, Z. I., Daniel, S. E., Lees, A. J., Marsden, D. C., Jenner, P., and Halliwell, B.
(1997a). A generalised increase in protein carbonyls in the brain in Parkinson’s
but not incidental Lewy body disease. J. Neurochem. 69, 1326–1329. doi:
10.1046/j.1471-4159.1997.69031326.x
Alam, Z. I., Jenner, A., Daniel, S. E., Lees, A. J., Cairns, N., Marsden, C. D., et al.
(1997b). Oxidative DNA damage in the parkinsonian brain: an apparent selec-
tive increase in 8-hydroxyguanine levels in substantia nigra. J. Neurochem. 69,
1196–1203. doi: 10.1046/j.1471-4159.1997.69031196.x
Alim, M. A., Hossain, M. S., Arima, K., Takeda, K., Izumiyama, Y., Nakamura, M.,
et al. (2002). Tubulin seeds alpha-synuclein fibril formation. J. Biol. Chem. 277,
2112–2117. doi: 10.1074/jbc.M102981200
Alim, M. A., Ma, Q.-L., Takeda, K., Aizawa, T., Matsubara, M., Nakamura,
M., et al. (2004). Demonstration of a role for alpha-synuclein as a func-
tional microtubule-associated protein. J. Alzheimers Dis. 6, 435–442. discussion:
443–439.
Andreini, C., Bertini, I., Cavallaro, G., Holliday, G. L., and Thornton, J. M. (2008).
Metal ions in biological catalysis: from enzyme databases to general principles.
J. Biol. Inorg. Chem. 13, 1205–1218. doi: 10.1007/s00775-008-0404-5
Appel-Cresswell, S., Vilarino-Guell, C., Encarnacion, M., Sherman, H., Yu, I., Shah,
B., et al. (2013). Alpha-synuclein p.H50Q, a novel pathogenic mutation for
Parkinson’s disease.Mov. Disord. 28, 811–813. doi: 10.1002/mds.25421
Arima, K., Hirai, S., Sunohara, N., Aoto, K., Izumiyama, Y., Ueda, K., et al. (1999).
Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-
epitopes in lewy bodies in sporadic Parkinson’s disease and in dementia with
Lewy bodies. Brain Res. 843, 53–61. doi: 10.1016/S0006-8993(99)01848-X
Arredondo,M., andNunez,M. T. (2005). Iron and coppermetabolism.Mol. Aspects
Med. 26, 313–327. doi: 10.1016/j.mam.2005.07.010
Bains, J. S., and Shaw, C. A. (1997). Neurodegenerative disorders in humans: the
role of glutathione in oxidative stress-mediated neuronal death. Brain Res. Brain
Res. Rev. 25, 335–358. doi: 10.1016/S0165-0173(97)00045-3
Bancher, C., Braak, H., Fischer, P., and Jellinger, K. A. (1993). Neuropathological
staging of Alzheimer lesions and intellectual status in Alzheimer’s and
Parkinson’s disease patients. Neurosci. Lett. 162, 179–182. doi: 10.1016/0304-
3940(93)90590-H
Bargmann, C. I. (1998). Neurobiology of the Caenorhabditis elegans genome.
Science 282, 2028–2033. doi: 10.1126/science.282.5396.2028
Ben-Shachar, D., and Youdim, M. B. (1991). Intranigral iron injection induces
behavioral and biochemical “parkinsonism” in rats. J. Neurochem. 57,
2133–2135. doi: 10.1111/j.1471-4159.1991.tb06432.x
Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E.,
et al. (2003). Mutations in the DJ-1 gene associated with autosomal recessive
early-onset parkinsonism. Science 299, 256–259. doi: 10.1126/science.1077209
Braak, H., Del Tredici, K., Rub, U., De Vos, R. A., Jansen Steur, E. N., and Braak,
E. (2003). Staging of brain pathology related to sporadic Parkinson’s disease.
Neurobiol. Aging 24, 197–211. doi: 10.1016/S0197-4580(02)00065-9
Brandt, R., Gergou, A., Wacker, I., Fath, T., and Hutter, H. (2009). A Caenorhabditis
elegans model of tau hyperphosphorylation: induction of developmental
defects by transgenic overexpression of Alzheimer’s disease-like modified tau.
Neurobiol. Aging 30, 22–33. doi: 10.1016/j.neurobiolaging.2007.05.011
Bras, J., Simon-Sanchez, J., Federoff, M., Morgadinho, A., Januario, C., Ribeiro, M.,
et al. (2009). Lack of replication of association between GIGYF2 variants and
Parkinson disease. Hum. Mol. Genet. 18, 341–346. doi: 10.1093/hmg/ddn340
Braungart, E., Gerlach, M., Riederer, P., Baumeister, R., and Hoener, M. C. (2004).
Caenorhabditis elegansMPP+model of Parkinson’s disease for high-throughput
drug screenings. Neurodegener. Dis. 1, 175–183. doi: 10.1159/000080983
Brenner, S. (1974). The genetics of Caenorhabditis elegans. Genetics 77, 71–94.
Buter, T. C., van den Hout, A., Matthews, F. E., Larsen, J. P., Brayne,
C., and Aarsland, D. (2008). Dementia and survival in Parkinson
disease: a 12-year population study. Neurology 70, 1017–1022. doi:
10.1212/01.wnl.0000306632.43729.24
Cairo, G., Recalcati, S., Pietrangelo, A., and Minotti, G. (2002). The iron regulatory
proteins: targets and modulators of free radical reactions and oxidative damage.
Free Radic. Biol. Med. 32, 1237–1243. doi: 10.1016/S0891-5849(02)00825-0
Camakaris, J., Voskoboinik, I., and Mercer, J. F. (1999). Molecular mechanisms
of copper homeostasis. Biochem. Biophys. Res. Commun. 261, 225–232. doi:
10.1006/bbrc.1999.1073
Cao, S., Gelwix, C. C., Caldwell, K. A., and Caldwell, G. A. (2005). Torsin-mediated
protection from cellular stress in the dopaminergic neurons of Caenorhabditis
elegans. J. Neurosci. 25, 3801–3812. doi: 10.1523/JNEUROSCI.5157-
04.2005
Cappelletti, G., Surrey, T., and Maci, R. (2005). The parkinsonism producing neu-
rotoxin MPP+ affects microtubule dynamics by acting as a destabilising factor.
FEBS Lett. 579, 4781–4786. doi: 10.1016/j.febslet.2005.07.058
Cartelli, D., Casagrande, F., Busceti, C. L., Bucci, D., Molinaro, G., Traficante, A.,
et al. (2013). Microtubule alterations occur early in experimental parkinsonism
and the microtubule stabilizer epothilone D is neuroprotective. Sci. Rep. 3:1837.
doi: 10.1038/srep01837
Frontiers in Aging Neuroscience www.frontiersin.org May 2014 | Volume 6 | Article 89 | 10
Chege and McColl Caenorhabditis elegans and Parkinson’s disease
Catoire, H., Dion, P. A., Xiong, L., Amari, M., Gaudet, R., Girard, S. L., et al.
(2011). Restless legs syndrome-associated MEIS1 risk variant influences iron
homeostasis. Ann. Neurol. 70, 170–175. doi: 10.1002/ana.22435
Chalfie, M., Tu, Y., Euskirchen, G., Ward, W. W., and Prasher, D. C. (1994). Green
fluorescent protein as a marker for gene expression. Science 263, 802–805. doi:
10.1126/science.8303295
Chartier-Harlin, M. C., Dachsel, J. C., Vilarino-Guell, C., Lincoln, S. J., Lepretre,
F., Hulihan, M. M., et al. (2011). Translation initiator EIF4G1 muta-
tions in familial Parkinson disease. Am. J. Hum. Genet. 89, 398–406. doi:
10.1016/j.ajhg.2011.08.009
Chew, Y. L., Fan, X., Gotz, J., and Nicholas, H. R. (2013). PTL-1 regulates neu-
ronal integrity and lifespan in C. elegans. J. Cell Sci. 126, 2079–2091. doi:
10.1242/jcs.jcs124404
Cobbold, C., Coventry, J., Ponnambalam, S., and Monaco, A. P. (2004). Actin
and microtubule regulation of trans-Golgi network architecture, and copper-
dependent protein transport to the cell surface. Mol. Membr. Biol. 21, 59–66.
doi: 10.1080/096870310001607350
Connor, J. R., Snyder, B. S., Arosio, P., Loeffler, D. A., and Lewitt, P. (1995). A
quantitative analysis of isoferritins in select regions of aged, parkinsonian, and
Alzheimer’s diseased brains. J. Neurochem. 65, 717–724. doi: 10.1046/j.1471-
4159.1995.65020717.x
Consortium, C. E. S. (1998). Genome sequence of the nematode C. elegans: a
platform for investigating biology. Science 282, 2012–2018. doi: 10.1126/sci-
ence.282.5396.2012
Cooper, A. A., Gitler, A. D., Cashikar, A., Haynes, C. M., Hill, K. J., Bhullar, B., et al.
(2006). Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss
in Parkinson’s models. Science 313, 324–328. doi: 10.1126/science.1129462
Crouch, P. J., Savva, M. S., Hung, L. W., Donnelly, P. S., Mot, A. I., Parker, S. J., et al.
(2011). The Alzheimer’s therapeutic PBT2 promotes amyloid-beta degradation
and GSK3 phosphorylation via a metal chaperone activity. J. Neurochem. 119,
220–230. doi: 10.1111/j.1471-4159.2011.07402.x
Culetto, E., and Sattelle, D. B. (2000). A role for Caenorhabditis elegans in under-
standing the function and interactions of human disease genes. Hum. Mol.
Genet. 9, 869–877. doi: 10.1093/hmg/9.6.869
Curtis, A. R., Fey, C., Morris, C. M., Bindoff, L. A., Ince, P. G., Chinnery, P.
F., et al. (2001). Mutation in the gene encoding ferritin light polypeptide
causes dominant adult-onset basal ganglia disease.Nat. Genet. 28, 350–354. doi:
10.1038/ng571
Dexter, D. T., Carayon, A., Javoy-Agid, F., Agid, Y., Wells, F. R., Daniel, S. E.,
et al. (1991). Alterations in the levels of iron, ferritin and other trace metals
in Parkinson’s disease and other neurodegenerative diseases affecting the basal
ganglia. Brain 114(pt 4), 1953–1975. doi: 10.1093/brain/114.4.1953
Dexter, D. T., Carter, C. J., Wells, F. R., Javoy-Agid, F., Agid, Y., Lees, A., et al.
(1989a). Basal lipid peroxidation in substantia nigra is increased in Parkinson’s
disease. J. Neurochem. 52, 381–389. doi: 10.1111/j.1471-4159.1989.tb
09133.x
Dexter, D. T., Holley, A. E., Flitter, W. D., Slater, T. F., Wells, F. R., Daniel, S.
E., et al. (1994). Increased levels of lipid hydroperoxides in the parkinso-
nian substantia nigra: an HPLC and ESR study. Mov. Disord. 9, 92–97. doi:
10.1002/mds.870090115
Dexter, D. T., Wells, F. R., Lees, A. J., Agid, F., Agid, Y., Jenner, P., et al. (1989b).
Increased nigral iron content and alterations in other metal ions occurring in
brain in Parkinson’s disease. J. Neurochem. 52, 1830–1836. doi: 10.1111/j.1471-
4159.1989.tb07264.x
Dixit, R., Ross, J. L., Goldman, Y. E., and Holzbaur, E. L. F. (2008). Differential
regulation of dynein and kinesin motor proteins by tau. Science 319, 1086–1089.
doi: 10.1126/science.1152993
Dorman, J. B., Albinder, B., Shroyer, T., and Kenyon, C. (1995). The age-1 and daf-2
genes function in a common pathway to control the lifespan of Caenorhabditis
elegans. Genetics 141, 1399–1406.
Duka, T., Duka, V., Joyce, J. N., and Sidhu, A. (2009). Alpha-Synuclein contributes
to GSK-3beta-catalyzed Tau phosphorylation in Parkinson’s disease models.
FASEB J. 23, 2820–2830. doi: 10.1096/fj.08-120410
Ebneth, A., Godemann, R., Stamer, K., Illenberger, S., Trinczek, B., andMandelkow,
E. (1998). Overexpression of tau protein inhibits kinesin-dependent traffick-
ing of vesicles, mitochondria, and endoplasmic reticulum: implications for
Alzheimer’s disease. J. Cell Biol. 143, 777–794. doi: 10.1083/jcb.143.3.777
Edvardson, S., Cinnamon, Y., Ta-Shma, A., Shaag, A., Yim, Y. I., Zenvirt, S., et al.
(2012). A deleterious mutation in DNAJC6 encoding the neuronal-specific
clathrin-uncoating co-chaperone auxilin, is associated with juvenile parkinson-
ism. PLoS ONE 7:e36458. doi: 10.1371/journal.pone.0036458
Edwards, T. L., Scott, W. K., Almonte, C., Burt, A., Powell, E. H., Beecham, G. W.,
et al. (2010). Genome-wide association study confirms SNPs in SNCA and the
MAPT region as common risk factors for Parkinson disease. Ann. Hum. Genet.
74, 97–109. doi: 10.1111/j.1469-1809.2009.00560.x
Ellis, H.M., andHorvitz, H. R. (1986). Genetic control of programmed cell death in
the nematode C. elegans. Cell 44, 817–829. doi: 10.1016/0092-8674(86)90004-8
Faber, P. W., Alter, J. R., Macdonald, M. E., and Hart, A. C. (1999). Polyglutamine-
mediated dysfunction and apoptotic death of a Caenorhabditis elegans sensory
neuron. Proc. Natl. Acad. Sci. U.S.A. 96, 179–184. doi: 10.1073/pnas.96.1.179
Fang, F. C. (2004). Antimicrobial reactive oxygen and nitrogen species: concepts
and controversies. Nat. Rev. Microbiol. 2, 820–832. doi: 10.1038/nrmicro1004
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., and Mello, C.
C. (1998). Potent and specific genetic interference by double-stranded RNA in
Caenorhabditis elegans. Nature 391, 806–811. doi: 10.1038/35888
Forno, L. S. (1996). Neuropathology of Parkinson’s disease. J. Neuropathol. Exp.
Neurol. 55, 259–272. doi: 10.1097/00005072-199603000-00001
Freeman, L. R., and Keller, J. N. (2012). Oxidative stress and cerebral endothelial
cells: regulation of the blood-brain-barrier and antioxidant based interventions.
Biochim. Biophys. Acta 1822, 822–829. doi: 10.1016/j.bbadis.2011.12.009
Friedman, D. B., and Johnson, T. E. (1988). A mutation in the age-1 gene
in Caenorhabditis elegans lengthens life and reduces hermaphrodite fertility.
Genetics 118, 75–86.
Fuxe, K., and Jonsson, G. (1973). The histochemical fluorescence method
for the demonstration of catecholamines. Theory, practice and application.
J. Histochem. Cytochem. 21, 293–311. doi: 10.1177/21.4.293
Geddes, J. W. (2005). alpha-Synuclein: a potent inducer of tau pathology. Exp.
Neurol. 192, 244–250. doi: 10.1016/j.expneurol.2004.12.002
Gerlach, M., Ben-Shachar, D., Riederer, P., and Youdim, M. B. (1994). Altered brain
metabolism of iron as a cause of neurodegenerative diseases? J. Neurochem. 63,
793–807. doi: 10.1046/j.1471-4159.1994.63030793.x
Giasson, B. I., Forman, M. S., Higuchi, M., Golbe, L. I., Graves, C. L., Kotzbauer,
P. T., et al. (2003). Initiation and synergistic fibrillization of tau and alpha-
synuclein. Science 300, 636–640. doi: 10.1126/science.1082324
Gkouvatsos, K., Papanikolaou, G., and Pantopoulos, K. (2012). Regulation of iron
transport and the role of transferrin. Biochim. Biophys. Acta 1820, 188–202. doi:
10.1016/j.bbagen.2011.10.013
Goedert, C., Baur, C. P., Ahringer, J., Jakes, R., Hasegawa, M., Spillantini, M. G.,
et al. (1996). PTL-1, a microtubule-associated protein with tau-like repeats from
the nematode Caenorhabditis elegans. J. Cell Sci. 109, 2661–2672.
Good, P. F., Olanow, C. W., and Perl, D. P. (1992). Neuromelanin-containing neu-
rons of the substantia nigra accumulate iron and aluminum in Parkinson’s
disease: a LAMMA study. Brain Res. 593, 343–346. doi: 10.1016/0006-
8993(92)91334-B
Gordon, P., Hingula, L., Krasny, M. L., Swienckowski, J. L., Pokrywka, N. J., and
Raley-Susman, K. M. (2008). The invertebrate microtubule-associated pro-
tein PTL-1 functions in mechanosensation and development in Caenorhabditis
elegans. Dev. Genes Evol. 218, 541–551. doi: 10.1007/s00427-008-0250-z
Gotz, M. E., Double, K., Gerlach, M., Youdim, M. B., and Riederer, P. (2004). The
relevance of iron in the pathogenesis of Parkinson’s disease. Ann. N.Y. Acad. Sci.
1012, 193–208. doi: 10.1196/annals.1306.017
Haacke, E. M., Ayaz, M., Khan, A., Manova, E. S., Krishnamurthy, B., Gollapalli,
L., et al. (2007). Establishing a baseline phase behavior in magnetic resonance
imaging to determine normal vs. abnormal iron content in the brain. J. Magn.
Reson. Imaging 26, 256–264. doi: 10.1002/jmri.22987
Halliwell, B. (2001). Role of free radicals in the neurodegenerative diseases: ther-
apeutic implications for antioxidant treatment. Drugs Aging 18, 685–716. doi:
10.2165/00002512-200118090-00004
Halliwell, B., and Gutteridge, J. M. (1986). Oxygen free radicals and iron in relation
to biology and medicine: some problems and concepts. Arch. Biochem. Biophys.
246, 501–514. doi: 10.1016/0003-9861(86)90305-X
Hamamichi, S., Rivas, R. N., Knight, A. L., Cao, S., Caldwell, K. A., and Caldwell,
G. A. (2008). Hypothesis-based RNAi screening identifies neuroprotective genes
in a Parkinson’s disease model. Proc. Natl. Acad. Sci. U.S.A. 105, 728–733. doi:
10.1073/pnas.0711018105
Harris, Z. L., Klomp, L. W., and Gitlin, J. D. (1998). Aceruloplasminemia: an inher-
ited neurodegenerative disease with impairment of iron homeostasis. Am. J.
Clin. Nutr. 67, 972S–977S.
Frontiers in Aging Neuroscience www.frontiersin.org May 2014 | Volume 6 | Article 89 | 11
Chege and McColl Caenorhabditis elegans and Parkinson’s disease
Hashimoto, M., Hsu, L. J., Xia, Y., Takeda, A., Sisk, A., Sundsmo, M., et al. (1999).
Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-
synuclein in vitro.Neuroreport 10, 717–721. doi: 10.1097/00001756-199903170-
00011
Healy, D. G., Abou-Sleiman, P. M., Casas, J. P., Ahmadi, K. R., Lynch, T., Gandhi,
S., et al. (2006). UCHL-1 is not a Parkinson’s disease susceptibility gene. Ann.
Neurol. 59, 627–633. doi: 10.1002/ana.20757
Hedgecock, E. M., Sulston, J. E., and Thomson, J. N. (1983). Mutations affecting
programmed cell deaths in the nematode Caenorhabditis elegans. Science 220,
1277–1279. doi: 10.1126/science.6857247
Hekimi, S., Lapointe, J., andWen, Y. (2011). Taking a “good” look at free radicals in
the aging process. Trends Cell Biol. 21, 569–576. doi: 10.1016/j.tcb.2011.06.008
Hely, M. A., Reid, W. G., Adena, M. A., Halliday, G. M., and Morris, J. G.
(2008). The Sydney multicenter study of Parkinson’s disease: the inevitability
of dementia at 20 years.Mov. Disord. 23, 837–844. doi: 10.1002/mds.21956
Hills, T., Brockie, P. J., and Maricq, A. V. (2004). Dopamine and glutamate con-
trol area-restricted search behavior in Caenorhabditis elegans. J. Neurosci. 24,
1217–1225. doi: 10.1523/JNEUROSCI.1569-03.2004
Hirtz, D., Thurman, D. J., Gwinn-Hardy, K., Mohamed, M., Chaudhuri, A. R., and
Zalutsky, R. (2007). How common are the “common” neurologic disorders?
Neurology 68, 326–337. doi: 10.1212/01.wnl.0000252807.38124.a3
Hornykiewicz, O., and Kish, S. J. (1987). Biochemical pathophysiology of
Parkinson’s disease. Adv. Neurol. 45, 19–34.
Hwang, O. (2013). Role of oxidative stress in Parkinson’s disease. Exp. Neurobiol.
22, 11–17. doi: 10.5607/en.2013.22.1.11
Irizarry, M. C., Growdon, W., Gomez-Isla, T., Newell, K., George, J. M., Clayton,
D. F., et al. (1998). Nigral and cortical Lewy bodies and dystrophic nigral
neurites in Parkinson’s disease and cortical Lewy body disease contain alpha-
synuclein immunoreactivity. J. Neuropathol. Exp. Neurol. 57, 334–337. doi:
10.1097/00005072-199804000-00005
Iwai, A., Masliah, E., Yoshimoto, M., Ge, N., Flanagan, L., De Silva, H. A., et al.
(1995). The precursor protein of non-A beta component of Alzheimer’s dis-
ease amyloid is a presynaptic protein of the central nervous system. Neuron 14,
467–475. doi: 10.1016/0896-6273(95)90302-X
Jancsik, V., Filliol, D., and Rendon, A. (1996). Tau proteins bind to kinesin and
modulate its activation by microtubules. Neurobiology (Bp) 4, 417–429.
Janvin, C. C., Larsen, J. P., Aarsland, D., and Hugdahl, K. (2006). Subtypes of mild
cognitive impairment in Parkinson’s disease: progression to dementia. Mov.
Disord. 21, 1343–1349. doi: 10.1002/mds.20974
Jenner, P. (2003). Oxidative stress in Parkinson’s disease. Ann. Neurol. 53(Suppl. 3),
S26–S36. discussion: S36–S38. doi: 10.1002/ana.10483
Jenner, P., and Olanow, C. W. (1996). Oxidative stress and the patho-
genesis of Parkinson’s disease. Neurology 47, 161S–170S. doi:
10.1212/WNL.47.6_Suppl_3.161S
Jensen, P. H., Hager, H., Nielsen, M. S., Hojrup, P., Gliemann, J., and Jakes, R.
(1999). alpha-synuclein binds to Tau and stimulates the protein kinase A-
catalyzed tau phosphorylation of serine residues 262 and 356. J. Biol. Chem.
274, 25481–25489. doi: 10.1074/jbc.274.36.25481
Jiang, D., Shi, S., Zhang, L., Liu, L., Ding, B., Zhao, B., et al. (2013). Inhibition of
the Fe(III)-catalyzed dopamine oxidation by ATP and its relevance to oxida-
tive stress in Parkinson’s disease. ACS Chem. Neurosci. 4, 1305–1313. doi:
10.1021/cn400105d
Joachim, C. L., Morris, J. H., Kosik, K. S., and Selkoe, D. J. (1987). Tau antisera
recognize neurofibrillary tangles in a range of neurodegenerative disorders.Ann.
Neurol. 22, 514–520. doi: 10.1002/ana.410220411
Jomova, K., Vondrakova, D., Lawson, M., and Valko, M. (2010). Metals, oxidative
stress and neurodegenerative disorders. Mol. Cell. Biochem. 345, 91–104. doi:
10.1007/s11010-010-0563-x
Junn, E., Taniguchi, H., Jeong, B. S., Zhao, X., Ichijo, H., and Mouradian, M.
M. (2005). Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating
kinase 1 activity and cell death. Proc. Natl. Acad. Sci. U.S.A. 102, 9691–9696.
doi: 10.1073/pnas.0409635102
Kamp, F., Exner, N., Lutz, A. K., Wender, N., Hegermann, J., Brunner, B., et al.
(2010). Inhibition of mitochondrial fusion by alpha-synuclein is rescued by
PINK1, Parkin andDJ-1. EMBO J. 29, 3571–3589. doi: 10.1038/emboj.2010.223
Kanaan, N. M., Morfini, G., Pigino, G., Lapointe, N. E., Andreadis, A., Song, Y.,
et al. (2012). Phosphorylation in the amino terminus of tau prevents inhibi-
tion of anterograde axonal transport.Neurobiol. Aging 33, 826.e15–826.e30. doi:
10.1016/j.neurobiolaging.2011.06.006
Karpinar, D. P., Balija, M. B., Kugler, S., Opazo, F., Rezaei-Ghaleh, N., Wender, N.,
et al. (2009). Pre-fibrillar alpha-synuclein variants with impaired beta-structure
increase neurotoxicity in Parkinson’s disease models. EMBO J. 28, 3256–3268.
doi: 10.1038/emboj.2009.257
Kaur, D., Yantiri, F., Rajagopalan, S., Kumar, J., Mo, J. Q., Boonplueang, R., et al.
(2003). Genetic or pharmacological iron chelation prevents MPTP-induced
neurotoxicity in vivo: a novel therapy for Parkinson’s disease. Neuron 37,
899–909. doi: 10.1016/S0896-6273(03)00126-0
Kenyon, C., Chang, J., Gensch, E., Rudner, A., and Tabtiang, R. (1993). A C. ele-
gans mutant that lives twice as long as wild type.Nature 366, 461–464. doi:
10.1038/366461a0
Kepp, K. P. (2012). Bioinorganic chemistry of Alzheimer’s disease. Chem. Rev. 112,
5193–5239. doi: 10.1021/cr300009x
Kidd, M. (1963). Paired helical filaments in electron microscopy of Alzheimer’s
disease. Nature 197, 192–193. doi: 10.1038/197192b0
Kimura, K. D., Tissenbaum, H. A., Liu, Y., and Ruvkun, G. (1997). daf-2, an insulin
receptor-like gene that regulates longevity and diapause in Caenorhabditis
elegans. Science 277, 942–946. doi: 10.1126/science.277.5328.942
Kish, S. J., Shannak, K., and Hornykiewicz, O. (1988). Uneven pattern of
dopamine loss in the striatum of patients with idiopathic Parkinson’s disease.
Pathophysiologic and clinical implications. N. Engl. J. Med. 318, 876–880. doi:
10.1056/NEJM198804073181402
Kokhan, V. S., Afanasyeva, M. A., and Van’kin, G. I. (2012). alpha-Synuclein knock-
out mice have cognitive impairments. Behav. Brain Res. 231, 226–230. doi:
10.1016/j.bbr.2012.03.026
Koroglu, C., Baysal, L., Cetinkaya, M., Karasoy, H., and Tolun, A. (2013).
DNAJC6 is responsible for juvenile parkinsonism with phenotypic variability.
Parkinsonism Relat. Disord. 19, 320–324. doi: 10.1016/j.parkreldis.2012.11.006
Kosik, K. S., and Finch, E. A. (1987). MAP2 and tau segregate into dendritic and
axonal domains after the elaboration of morphologically distinct neurites: an
immunocytochemical study of cultured rat cerebrum. J. Neurosci. 7, 3142–3153.
Kraemer, B. C., Zhang, B., Leverenz, J. B., Thomas, J. H., Trojanowski, J. Q., and
Schellenberg, G. D. (2003). Neurodegeneration and defective neurotransmis-
sion in a Caenorhabditis elegansmodel of tauopathy. Proc. Natl. Acad. Sci. U.S.A.
100, 9980–9985. doi: 10.1073/pnas.1533448100
Krebs, C. E., Karkheiran, S., Powell, J. C., Cao, M., Makarov, V., Darvish, H.,
et al. (2013). The Sac1 domain of SYNJ1 identified mutated in a family with
early-onset progressive Parkinsonism with generalized seizures. Hum. Mutat.
34, 1200–1207. doi: 10.1002/humu.22372
Kristinsson, J., Snaedal, J., Torsdottir, G., and Johannesson, T. (2012).
Ceruloplasmin and iron in Alzheimer’s disease and Parkinson’s disease: a synop-
sis of recent studies. Neuropsychiatr. Dis. Treat. 8, 515–521. doi: 10.2147/NDT.
S34729
Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S., et al. (1998).
Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease.
Nat. Genet. 18, 106–108. doi: 10.1038/ng0298-106
Kuwahara, T., Koyama, A., Gengyo-Ando, K., Masuda, M., Kowa, H., Tsunoda,
M., et al. (2006). Familial Parkinson mutant alpha-synuclein causes dopamine
neuron dysfunction in transgenic Caenorhabditis elegans. J. Biol. Chem. 281,
334–340. doi: 10.1074/jbc.M504860200
Kuwahara, T., Koyama, A., Koyama, S., Yoshina, S., Ren, C. H., Kato, T., et al. (2008).
A systematic RNAi screen reveals involvement of endocytic pathway in neu-
ronal dysfunction in alpha-synuclein transgenic C. elegans. Hum. Mol. Genet.
17, 2997–3009. doi: 10.1093/hmg/ddn198
Lai, C. H., Chou, C. Y., Ch’ang, L. Y., Liu, C. S., and Lin, W. (2000).
Identification of novel human genes evolutionarily conserved in Caenorhabditis
elegans by comparative proteomics. Genome Res. 10, 703–713. doi: 10.1101/gr.
10.5.703
Lakso, M., Vartiainen, S., Moilanen, A. M., Sirvio, J., Thomas, J. H., Nass, R., et al.
(2003). Dopaminergic neuronal loss and motor deficits in Caenorhabditis ele-
gans overexpressing human alpha-synuclein. J. Neurochem. 86, 165–172. doi:
10.1046/j.1471-4159.2003.01809.x
Lannfelt, L., Blennow, K., Zetterberg, H., Batsman, S., Ames, D., Harrison,
J., et al. (2008). Safety, efficacy, and biomarker findings of PBT2 in tar-
geting Abeta as a modifying therapy for Alzheimer’s disease: a phase IIa,
double-blind, randomised, placebo-controlled trial. Lancet Neurol. 7, 779–786.
doi: 10.1016/S1474-4422(08)70167-4
Lapointe, N. E., Morfini, G., Pigino, G., Gaisina, I. N., Kozikowski, A. P., Binder, L.
I., et al. (2009). The amino terminus of tau inhibits kinesin-dependent axonal
Frontiers in Aging Neuroscience www.frontiersin.org May 2014 | Volume 6 | Article 89 | 12
Chege and McColl Caenorhabditis elegans and Parkinson’s disease
transport: implications for filament toxicity. J. Neurosci. Res. 87, 440–451. doi:
10.1002/jnr.21850
Lee, D. W., and Andersen, J. K. (2010). Iron elevations in the aging Parkinsonian
brain: a consequence of impaired iron homeostasis? J. Neurochem. 112, 332–339.
doi: 10.1111/j.1471-4159.2009.06470.x
Lee, F. J., Liu, F., Pristupa, Z. B., and Niznik, H. B. (2001). Direct binding and
functional coupling of alpha-synuclein to the dopamine transporters accel-
erate dopamine-induced apoptosis. FASEB J. 15, 916–926. doi: 10.1096/fj.00-
0334com
Lei, P., Ayton, S., Finkelstein, D. I., Spoerri, L., Ciccotosto, G. D., Wright, D. K.,
et al. (2012). Tau deficiency induces parkinsonism with dementia by impairing
APP-mediated iron export. Nat. Med. 18, 291–295. doi: 10.1038/nm.2613
Li, W. W., Yang, R., Guo, J. C., Ren, H. M., Zha, X. L., Cheng, J. S., et al. (2007).
Localization of alpha-synuclein to mitochondria within midbrain of mice.
Neuroreport 18, 1543–1546. doi: 10.1097/WNR.0b013e3282f03db4
Liochev, S. I., and Fridovich, I. (1994). The role of O2.- in the production of
HO.: in vitro and in vivo. Free Radic. Biol. Med. 16, 29–33. doi: 10.1016/0891-
5849(94)90239-9
Lotharius, J., and O’Malley, K. L. (2000). The parkinsonism-inducing drug
1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A
novel mechanism of toxicity. J. Biol. Chem. 275, 38581–38588. doi:
10.1074/jbc.M005385200
Luo, Y., Umegaki, H., Wang, X., Abe, R., and Roth, G. S. (1998). Dopamine induces
apoptosis through an oxidation-involved SAPK/JNK activation pathway. J. Biol.
Chem. 273, 3756–3764. doi: 10.1074/jbc.273.6.3756
Magnani, E., Fan, J., Gasparini, L., Golding, M., Williams, M., Schiavo, G., et al.
(2007). Interaction of tau protein with the dynactin complex. EMBO J. 26,
4546–4554. doi: 10.1038/sj.emboj.7601878
Mandelkow, E. M., Stamer, K., Vogel, R., Thies, E., and Mandelkow, E. (2003).
Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses.
Neurobiol. Aging 24, 1079–1085. doi: 10.1016/j.neurobiolaging.2003.04.007
Marttila, R. J., Lorentz, H., and Rinne, U. K. (1988). Oxygen toxicity protecting
enzymes in Parkinson’s disease. Increase of superoxide dismutase-like activ-
ity in the substantia nigra and basal nucleus. J. Neurol. Sci. 86, 321–331. doi:
10.1016/0022-510X(88)90108-6
McColl, G., Roberts, B. R., Gunn, A. P., Perez, K. A., Tew, D. J., Masters, C. L.,
et al. (2009). The Caenorhabditis elegans A beta 1-42 model of Alzheimer dis-
ease predominantly expresses A beta 3-42. J. Biol. Chem. 284, 22697–22702. doi:
10.1074/jbc.C109.028514
McColl, G., Roberts, B. R., Pukala, T. L., Kenche, V. B., Roberts, C. M., Link, C. D.,
et al. (2012). Utility of an improved model of amyloid-beta (Abeta(1)(-)(4)(2))
toxicity in Caenorhabditis elegans for drug screening for Alzheimer’s disease.
Mol. Neurodegener. 7, 57. doi: 10.1186/1750-1326-7-57
McCormick, A. V., Wheeler, J. M., Guthrie, C. R., Liachko, N. F., and Kraemer,
B. C. (2013). Dopamine D2 receptor antagonism suppresses tau aggregation
and neurotoxicity. Biol. Psychiatry 73, 464–471. doi: 10.1016/j.biopsych.2012.
08.027
McDonald, P. W., Jessen, T., Field, J. R., and Blakely, R. D. (2006). Dopamine sig-
naling architecture in Caenorhabditis elegans. Cell. Mol. Neurobiol. 26, 593–618.
doi: 10.1007/s10571-006-9003-6
Moos, T., and Rosengren Nielsen, T. (2006). Ferroportin in the postnatal rat brain:
implications for axonal transport and neuronal export of iron. Semin. Pediatr.
Neurol. 13, 149–157. doi: 10.1016/j.spen.2006.08.003
Morfini, G., Pigino, G., Opalach, K., Serulle, Y., Moreira, J. E., Sugimori, M., et al.
(2007). 1-Methyl-4-phenylpyridinium affects fast axonal transport by activation
of caspase and protein kinase C. Proc. Natl. Acad. Sci. U.S.A. 104, 2442–2447.
doi: 10.1073/pnas.0611231104
Muntane, G., Dalfo, E., Martinez, A., and Ferrer, I. (2008). Phosphorylation
of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cor-
tex in Alzheimer’s disease, and in Parkinson’s disease and related alpha-
synucleinopathies. Neuroscience 152, 913–923. doi: 10.1016/j.neuroscience.
2008.01.030
Murakami, S., and Johnson, T. E. (1996). A genetic pathway conferring life
extension and resistance to UV stress in Caenorhabditis elegans. Genetics 143,
1207–1218.
Nagatsu, T. (1995). Tyrosine hydroxylase: human isoforms, structure and regula-
tion in physiology and pathology. Essays Biochem. 30, 15–35.
Nakajo, S., Shioda, S., Nakai, Y., and Nakaya, K. (1994). Localization of phospho-
neuroprotein 14 (PNP 14) and its mRNA expression in rat brain determined by
immunocytochemistry and in situ hybridization. Brain Res. Mol. Brain Res. 27,
81–86. doi: 10.1016/0169-328X(94)90187-2
Nass, R., Hall, D. H., Miller, D. M. 3rd., and Blakely, R. D. (2002). Neurotoxin-
induced degeneration of dopamine neurons in Caenorhabditis elegans. Proc.
Natl. Acad. Sci. U.S.A. 99, 3264–3269. doi: 10.1073/pnas.042497999
Nemani, V. M., Lu, W., Berge, V., Nakamura, K., Onoa, B., Lee, M. K., et al. (2010).
Increased expression of alpha-synuclein reduces neurotransmitter release by
inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65, 66–79. doi:
10.1016/j.neuron.2009.12.023
Niki, E. (2009). Lipid peroxidation: physiological levels and dual biological effects.
Free Radic. Biol. Med. 47, 469–484. doi: 10.1016/j.freeradbiomed.2009.05.032
Nunez,M. T., Urrutia, P., Mena, N., Aguirre, P., Tapia, V., and Salazar, J. (2012). Iron
toxicity in neurodegeneration. Biometals 25, 761–776. doi: 10.1007/s10534-012-
9523-0
Oakley, A. E., Collingwood, J. F., Dobson, J., Love, G., Perrott, H. R.,
Edwardson, J. A., et al. (2007). Individual dopaminergic neurons show
raised iron levels in Parkinson disease. Neurology 68, 1820–1825. doi:
10.1212/01.wnl.0000262033.01945.9a
Offen, D., Hochman, A., Gorodin, S., Ziv, I., Shirvan, A., Barzilai, A., et al. (1999).
Oxidative stress and neuroprotection in Parkinson’s disease: implications from
studies on dopamine-induced apoptosis. Adv. Neurol. 80, 265–269.
Olanow, C. W., and Arendash, G. W. (1994). Metals and free radicals in neurode-
generation. Curr. Opin. Neurol. 7, 548–558. doi: 10.1097/00019052-199412000-
00013
Orth, M., and Schapira, A. H. (2002). Mitochondrial involvement in Parkinson’s
disease. Neurochem. Int. 40, 533–541. doi: 10.1016/S0197-0186(01)00124-3
Pang, W. L., Kaur, A., Ratushny, A. V., Cvetkovic, A., Kumar, S., Pan, M., et al.
(2013). Metallochaperones regulate intracellular copper levels. PLoS Comput.
Biol. 9:e1002880. doi: 10.1371/journal.pcbi.1002880
Pankratz, N., Nichols, W. C., Uniacke, S. K., Halter, C., Rudolph, A., Shults, C.,
et al. (2002). Genome screen to identify susceptibility genes for Parkinson dis-
ease in a sample without parkin mutations. Am. J. Hum. Genet. 71, 124–135.
doi: 10.1086/341282
Pattison, D. I., Dean, R. T., and Davies, M. J. (2002). Oxidation of DNA, pro-
teins and lipids by DOPA, protein-bound DOPA, and related catechol(amine)s.
Toxicology 177, 23–37. doi: 10.1016/S0300-483X(02)00193-2
Pezzella, A., D’Ischia, M., Napolitano, A., Misuraca, G., and Prota, G. (1997).
Iron-mediated generation of the neurotoxin 6-hydroxydopamine quinone by
reaction of fatty acid hydroperoxides with dopamine: a possible contributory
mechanism for neuronal degeneration in Parkinson’s disease. J. Med. Chem. 40,
2211–2216. doi: 10.1021/jm970099t
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A.,
et al. (1997). Mutation in the alpha-synuclein gene identified in families with
Parkinson’s disease. Science 276, 2045–2047. doi: 10.1126/science.276.5321.2045
Ponting, C. P. (2001). Domain homologues of dopamine beta-hydroxylase and fer-
ric reductase: roles for iron metabolism in neurodegenerative disorders? Hum.
Mol. Genet. 10, 1853–1858. doi: 10.1093/hmg/10.17.1853
Pridgeon, J. W., Olzmann, J. A., Chin, L. S., and Li, L. (2007). PINK1 protects
against oxidative stress by phosphorylating mitochondrial chaperone TRAP1.
PLoS Biol. 5:e172. doi: 10.1371/journal.pbio.0050172
Proukakis, C., Dudzik, C. G., Brier, T., Mackay, D. S., Cooper, J. M., Millhauser,
G. L., et al. (2013). A novel alpha-synuclein missense mutation in Parkinson
disease. Neurology 80, 1062–1064. doi: 10.1212/WNL.0b013e31828727ba
Przedborski, S., Levivier, M., Jiang, H., Ferreira, M., Jackson-Lewis, V., Donaldson,
D., et al. (1995). Dose-dependent lesions of the dopaminergic nigrostriatal path-
way induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 67,
631–647. doi: 10.1016/0306-4522(95)00066-R
Pu, P., and Le, W. (2008). Dopamine neuron degeneration induced by MPP+ is
independent of CED-4 pathway inCaenorhabditis elegans. Cell Res. 18, 978–981.
doi: 10.1038/cr.2008.279
Qin, Z., Hu, D., Han, S., Reaney, S. H., Di Monte, D. A., and Fink, A. L. (2007).
Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation.
J. Biol. Chem. 282, 5862–5870. doi: 10.1074/jbc.M608126200
Quadri, M., Fang, M., Picillo, M., Olgiati, S., Breedveld, G. J., Graafland,
J., et al. (2013). Mutation in the SYNJ1 gene associated with autosomal
recessive, early-onset Parkinsonism. Hum. Mutat. 34, 1208–1215. doi:
10.1002/humu.22373
Rae, T. D., Schmidt, P. J., Pufahl, R. A., Culotta, V. C., and O’Halloran, T. V.
(1999). Undetectable intracellular free copper: the requirement of a copper
Frontiers in Aging Neuroscience www.frontiersin.org May 2014 | Volume 6 | Article 89 | 13
Chege and McColl Caenorhabditis elegans and Parkinson’s disease
chaperone for superoxide dismutase. Science 284, 805–808. doi: 10.1126/sci-
ence.284.5415.805
Rand, J. B., and Nonet, M. L. (1997). “Synaptic transmission,” in C. elegans II, 2nd
Edn., eds D. L. Riddle, T. Blumenthal, B. J. Meyer, and J. R. Priess. (New York,
NY: Cold Spring Harbor), 611–643.
Rangel, N. A., Lin, L., Rakariyatham, K., Bach, A., Trinh, K., Clement, M. H., et al.
(2012). Unincorporated iron pool is linked to oxidative stress and iron levels in
Caenorhabditis elegans. Biometals 25, 971–985. doi: 10.1007/s10534-012-9563-5
Recchia, A., Debetto, P., Negro, A., Guidolin, D., Skaper, S. D., and Giusti, P.
(2004). Alpha-synuclein and Parkinson’s disease. FASEB J. 18, 617–626. doi:
10.1096/fj.03-0338rev
Ren, Y., Liu, W., Jiang, H., Jiang, Q., and Feng, J. (2005). Selective vulnerability
of dopaminergic neurons to microtubule depolymerization. J. Biol. Chem. 280,
34105–34112. doi: 10.1074/jbc.M503483200
Riederer, P., Sofic, E., Rausch, W. D., Schmidt, B., Reynolds, G. P., Jellinger,
K., et al. (1989). Transition metals, ferritin, glutathione, and ascorbic acid
in parkinsonian brains. J. Neurochem. 52, 515–520. doi: 10.1111/j.1471-
4159.1989.tb09150.x
Ruan, Q., Harrington, A. J., Caldwell, K. A., Caldwell, G. A., and Standaert, D.
G. (2010). VPS41, a protein involved in lysosomal trafficking, is protective in
Caenorhabditis elegans and mammalian cellular models of Parkinson’s disease.
Neurobiol. Dis. 37, 330–338. doi: 10.1016/j.nbd.2009.10.011
Saggu, H., Cooksey, J., Dexter, D., Wells, F. R., Lees, A., Jenner, P., et al.
(1989). A selective increase in particulate superoxide dismutase activity in
parkinsonian substantia nigra. J. Neurochem. 53, 692–697. doi: 10.1111/j.1471-
4159.1989.tb11759.x
Saha, S., Guillily, M. D., Ferree, A., Lanceta, J., Chan, D., Ghosh, J., et al. (2009).
LRRK2modulates vulnerability tomitochondrial dysfunction inCaenorhabditis
elegans. J. Neurosci. 29, 9210–9218. doi: 10.1523/JNEUROSCI.2281-09.2009
Salazar, J., Mena, N., Hunot, S., Prigent, A., Alvarez-Fischer, D., Arredondo, M.,
et al. (2008). Divalent metal transporter 1 (DMT1) contributes to neurodegen-
eration in animal models of Parkinson’s disease. Proc. Natl. Acad. Sci. U.S.A. 105,
18578–18583. doi: 10.1073/pnas.0804373105
Samann, J., Hegermann, J., von Gromoff, E., Eimer, S., Baumeister, R., and
Schmidt, E. (2009). Caenorhabditits elegans LRK-1 and PINK-1 act antagonisti-
cally in stress response and neurite outgrowth. J. Biol. Chem. 284, 16482–16491.
doi: 10.1074/jbc.M808255200
Sanyal, S., Wintle, R. F., Kindt, K. S., Nuttley, W. M., Arvan, R., Fitzmaurice, P.,
et al. (2004). Dopamine modulates the plasticity of mechanosensory responses
in Caenorhabditis elegans. EMBO J. 23, 473–482. doi: 10.1038/sj.emboj.7600057
Sauer, H., and Oertel, W. H. (1994). Progressive degeneration of nigros-
triatal dopamine neurons following intrastriatal terminal lesions with 6-
hydroxydopamine: a combined retrograde tracing and immunocytochemical
study in the rat. Neuroscience 59, 401–415. doi: 10.1016/0306-4522(94)90605-X
Sawin, E. R., Ranganathan, R., and Horvitz, H. R. (2000). C. elegans locomo-
tory rate is modulated by the environment through a dopaminergic pathway
and by experience through a serotonergic pathway. Neuron 26, 619–631. doi:
10.1016/S0896-6273(00)81199-X
Schafer, W. R., and Kenyon, C. J. (1995). A calcium-channel homologue required
for adaptation to dopamine and serotonin in Caenorhabditis elegans. Nature
375, 73–78. doi: 10.1038/375073a0
Schneider, J. A., Li, J. L., Li, Y., Wilson, R. S., Kordower, J. H., and Bennett, D. A.
(2006). Substantia nigra tangles are related to gait impairment in older persons.
Ann. Neurol. 59, 166–173. doi: 10.1002/ana.20723
Sengstock, G. J., Olanow, C. W., Menzies, R. A., Dunn, A. J., and Arendash, G. W.
(1993). Infusion of iron into the rat substantia nigra: nigral pathology and dose-
dependent loss of striatal dopaminergic markers. J. Neurosci. Res. 35, 67–82. doi:
10.1002/jnr.490350109
Settivari, R., Levora, J., and Nass, R. (2009). The divalent metal transporter homo-
logues SMF-1/2 mediate dopamine neuron sensitivity in caenorhabditis elegans
models of manganism and parkinson disease. J. Biol. Chem. 284, 35758–35768.
doi: 10.1074/jbc.M109.051409
Settivari, R., VanDuyn, N., Levora, J., and Nass, R. (2013). The Nrf2/SKN-1-
dependent glutathione S-transferase pi homologue GST-1 inhibits dopamine
neuron degeneration in a Caenorhabditis elegans model of manganism.
Neurotoxicology 38, 51–60. doi: 10.1016/j.neuro.2013.05.014
Shemesh, O. A., Erez, H., Ginzburg, I., and Spira, M. E. (2008). Tau-induced
traffic jams reflect organelles accumulation at points of microtubule polar
mismatching. Traffic 9, 458–471. doi: 10.1111/j.1600-0854.2007.00695.x
Sies, H. (1991). Oxidative stress: from basic research to clinical application. Am. J.
Med. 91, 31S–38S. doi: 10.1016/0002-9343(91)90281-2
Simon-Sanchez, J., and Singleton, A. B. (2008). Sequencing analysis of
OMI/HTRA2 shows previously reported pathogenic mutations in neu-
rologically normal controls. Hum. Mol. Genet. 17, 1988–1993. doi:
10.1093/hmg/ddn096
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., et al.
(2003). alpha-Synuclein locus triplication causes Parkinson’s disease. Science
302:841. doi: 10.1126/science.1090278
Smeyne, M., and Smeyne, R. J. (2013). Glutathione metabolism and Parkinson’s
disease. Free Radic. Biol. Med. 62, 13–25. doi: 10.1016/j.freeradbiomed.2013.
05.001
Smith, Y., Wichmann, T., Factor, S. A., and Delong, M. R. (2012). Parkinson’s
disease therapeutics: new developments and challenges since the introduc-
tion of levodopa. Neuropsychopharmacology 37, 213–246. doi: 10.1038/npp.
2011.212
Sofic, E., Lange, K. W., Jellinger, K., and Riederer, P. (1992). Reduced and oxidized
glutathione in the substantia nigra of patients with Parkinson’s disease.Neurosci.
Lett. 142, 128–130. doi: 10.1016/0304-3940(92)90355-B
Sofic, E., Paulus, W., Jellinger, K., Riederer, P., and Youdim, M. B. (1991). Selective
increase of iron in substantia nigra zona compacta of parkinsonian brains.
J. Neurochem. 56, 978–982. doi: 10.1111/j.1471-4159.1991.tb02017.x
Sohal, R. S., and Orr, W. C. (2012). The redox stress hypothesis of aging. Free Radic.
Biol. Med. 52, 539–555. doi: 10.1016/j.freeradbiomed.2011.10.445
Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q., Jakes, R., and
Goedert, M. (1997). Alpha-synuclein in Lewy bodies. Nature 388, 839–840. doi:
10.1038/42166
Stamer, K., Vogel, R., Thies, E., Mandelkow, E., and Mandelkow, E. M.
(2002). Tau blocks traffic of organelles, neurofilaments, and APP vesicles
in neurons and enhances oxidative stress. J. Cell Biol. 156, 1051–1063. doi:
10.1083/jcb.200108057
Strauss, K. M., Martins, L. M., Plun-Favreau, H., Marx, F. P., Kautzmann, S., Berg,
D., et al. (2005). Loss of function mutations in the gene encoding Omi/HtrA2
in Parkinson’s disease. Hum. Mol. Genet. 14, 2099–2111. doi: 10.1093/hmg/
ddi215
Su, L. J., Auluck, P. K., Outeiro, T. F., Yeger-Lotem, E., Kritzer, J. A., Tardiff, D. F.,
et al. (2010). Compounds from an unbiased chemical screen reverse both ER-to-
Golgi trafficking defects and mitochondrial dysfunction in Parkinson’s disease
models. Dis. Model. Mech. 3, 194–208. doi: 10.1242/dmm.004267
Sulston, J., Dew, M., and Brenner, S. (1975). Dopaminergic neurons in
the nematode Caenorhabditis elegans. J. Comp. Neurol. 163, 215–226. doi:
10.1002/cne.901630207
Tan, E. K., Lin, C. H., Tai, C. H., Tan, L. C., Chen, M. L., Li, R., et al. (2009).
Non-synonymous GIGYF2 variants in Parkinson’s disease from two Asian
populations. Hum. Genet. 126, 425–430. doi: 10.1007/s00439-009-0678-x
Tardiff, D. F., Tucci, M. L., Caldwell, K. A., Caldwell, G. A., and Lindquist,
S. (2012). Different 8-hydroxyquinolines protect models of TDP-43 protein,
alpha-synuclein, and polyglutamine proteotoxicity through distinct mecha-
nisms. J. Biol. Chem. 287, 4107–4120. doi: 10.1074/jbc.M111.308668
Thomas, B., and Beal, M. F. (2007). Parkinson’s disease. Hum. Mol. Genet. 16,
R183–R194. doi: 10.1093/hmg/ddm159
Trinczek, B., Ebneth, A., Mandelkow, E. M., and Mandelkow, E. (1999). Tau regu-
lates the attachment/detachment but not the speed of motors in microtubule-
dependent transport of single vesicles and organelles. J. Cell Sci. 112(pt 14),
2355–2367.
Ueda, K., Fukushima, H., Masliah, E., Xia, Y., Iwai, A., Yoshimoto, M., et al. (1993).
Molecular cloning of cDNA encoding an unrecognized component of amy-
loid in Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 90, 11282–11286. doi:
10.1073/pnas.90.23.11282
Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M., Harvey, K., Gispert,
S., et al. (2004). Hereditary early-onset Parkinson’s disease caused by mutations
in PINK1. Science 304, 1158–1160. doi: 10.1126/science.1096284
Valentini, S., Cabreiro, F., Ackerman, D., Alam, M. M., Kunze, M. B., Kay, C. W.,
et al. (2012). Manipulation of in vivo iron levels can alter resistance to oxidative
stress without affecting ageing in the nematode C. elegans. Mech. Ageing Dev.
133, 282–290. doi: 10.1016/j.mad.2012.03.003
VanDuyn, N., Settivari, R., Levora, J., Zhou, S., Unrine, J., and Nass, R. (2013).
The metal transporter SMF-3/DMT-1 mediates aluminum-induced dopamine
neuron degeneration. J. Neurochem. 124, 147–157. doi: 10.1111/jnc.12072
Frontiers in Aging Neuroscience www.frontiersin.org May 2014 | Volume 6 | Article 89 | 14
Chege and McColl Caenorhabditis elegans and Parkinson’s disease
VanDuyn, N., Settivari, R., Wong, G., and Nass, R. (2010). SKN-1/Nrf2
inhibits dopamine neuron degeneration in a Caenorhabditis elegans model of
methylmercury toxicity. Toxicol. Sci. 118, 613–624. doi: 10.1093/toxsci/kfq285
van Ham, T. J., Thijssen, K. L., Breitling, R., Hofstra, R. M., Plasterk, R. H.,
and Nollen, E. A. (2008). C. elegans model identifies genetic modifiers of
alpha-synuclein inclusion formation during aging. PLoS Genet. 4:e1000027. doi:
10.1371/journal.pgen.1000027
Ved, R., Saha, S., Westlund, B., Perier, C., Burnam, L., Sluder, A., et al. (2005).
Similar patterns of mitochondrial vulnerability and rescue induced by genetic
modification of alpha-synuclein, parkin, and DJ-1 in Caenorhabditis elegans.
J. Biol. Chem. 280, 42655–42668. doi: 10.1074/jbc.M505910200
Vidal, R., Delisle, M. B., Rascol, O., and Ghetti, B. (2003). Hereditary ferritinopathy.
J. Neurol. Sci. 207, 110–111. doi: 10.1016/S0022-510X(02)00435-5
Vulpe, C., Levinson, B., Whitney, S., Packman, S., and Gitschier, J. (1993). Isolation
of a candidate gene for Menkes disease and evidence that it encodes a copper-
transporting ATPase. Nat. Genet. 3, 6–12. doi: 10.1038/ng0193-7
Vymazal, J., Righini, A., Brooks, R. A., Canesi, M., Mariani, C., Leonardi, M., et al.
(1999). T1 and T2 in the brain of healthy subjects, patients with Parkinson
disease, and patients with multiple system atrophy: relation to iron content.
Radiology 211, 489–495. doi: 10.1148/radiology.211.2.r99ma53489
Waldron, K. J., Rutherford, J. C., Ford, D., and Robinson, N. J. (2009).
Metalloproteins and metal sensing. Nature 460, 823–830. doi: 10.1038/nature
08300
Weingarten, M. D., Lockwood, A. H., Hwo, S. Y., and Kirschner, M. W. (1975). A
Protein Factor Essential for Microtubule Assembly. Proc. Natl. Acad. Sci. U.S.A.
72, 1858–1862. doi: 10.1073/pnas.72.5.1858
Weinshenker, D., Garriga, G., and Thomas, J. H. (1995). Genetic and pharmacolog-
ical analysis of neurotransmitters controlling egg laying inC. elegans. J. Neurosci.
15, 6975–6985.
Weintraub, D., Doshi, J., Koka, D., Davatzikos, C., Siderowf, A. D., Duda, J. E.,
et al. (2011). Neurodegeneration across stages of cognitive decline in Parkinson
disease. Arch. Neurol. 68, 1562–1568. doi: 10.1001/archneurol.2011.725
Wersinger, C., and Sidhu, A. (2003). Attenuation of dopamine transporter
activity by α-synuclein. Neurosci. Lett. 340, 189–192. doi: 10.1016/S0304-
3940(03)00097-1
White, J. G., Southgate, E., Thomson, J. N., and Brenner, S. (1986). The Structure
of the nervous system of the nematode Caenorhabditis elegans. Philos. Trans. R.
Soc. Lond. B Biol. Sci. 314, 1–340. doi: 10.1098/rstb.1986.0056
White, K., andMunro, H. N. (1988). Induction of ferritin subunit synthesis by iron
is regulated at both the transcriptional and translational levels. J. Biol. Chem.
263, 8938–8942.
Wischik, C.M., Novak,M., Thogersen, H. C., Edwards, P. C., Runswick,M. J., Jakes,
R., et al. (1988). Isolation of a fragment of tau derived from the core of the paired
helical filament of Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 85, 4506–4510.
doi: 10.1073/pnas.85.12.4506
Wooten, G. F. (1997). Functional anatomical and behavioral consequences of
dopamine receptor stimulation. Ann. N.Y. Acad. Sci. 835, 153–156. doi:
10.1111/j.1749-6632.1997.tb48626.x
Yoritaka, A., Hattori, N., Uchida, K., Tanaka, M., Stadtman, E. R., and Mizuno, Y.
(1996). Immunohistochemical detection of 4-hydroxynonenal protein adducts
in Parkinson disease. Proc. Natl. Acad. Sci. U.S.A. 93, 2696–2701. doi:
10.1073/pnas.93.7.2696
Yoshida, K., Furihata, K., Takeda, S., Nakamura, A., Yamamoto, K., Morita,
H., et al. (1995). A mutation in the ceruloplasmin gene is associated with
systemic hemosiderosis in humans. Nat. Genet. 9, 267–272. doi: 10.1038/
ng0395-267
Youdim, M. B., Ashkenazi, R., Ben-Shachar, D., and Yehuda, S. (1984). Modulation
of dopamine receptor in the striatum by iron: behavioral and biochemical
correlates. Adv. Neurol. 40, 159–170.
Zabetian, C. P., Hutter, C. M., Factor, S. A., Nutt, J. G., Higgins, D. S., Griffith, A.,
et al. (2007). Association analysis of MAPT H1 haplotype and subhaplotypes in
Parkinson’s disease. Ann. Neurol. 62, 137–144. doi: 10.1002/ana.21157
Zarranz, J. J., Alegre, J., Gomez-Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I.,
et al. (2004). The new mutation, E46K, of alpha-synuclein causes Parkinson
and Lewy body dementia. Ann. Neurol. 55, 164–173. doi: 10.1002/ana.
10795
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Received: 03 March 2014; accepted: 27 April 2014; published online: 19 May 2014.
Citation: Chege PM and McColl G (2014) Caenorhabditis elegans: a model to inves-
tigate oxidative stress and metal dyshomeostasis in Parkinson’s disease. Front. Aging
Neurosci. 6:89. doi: 10.3389/fnagi.2014.00089
This article was submitted to the journal Frontiers in Aging Neuroscience.
Copyright © 2014 Chege andMcColl. This is an open-access article distributed under
the terms of the Creative Commons Attribution License (CC BY). The use, distribu-
tion or reproduction in other forums is permitted, provided the original author(s)
or licensor are credited and that the original publication in this journal is cited, in
accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
Frontiers in Aging Neuroscience www.frontiersin.org May 2014 | Volume 6 | Article 89 | 15
